{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:31:17Z","timestamp":1790980277995,"version":"4.1.0"},"reference-count":433,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02810-5","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:02:44Z","timestamp":1788303764000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immune checkpoints and immunoregulation in metabolic diseases and cancers: pathological mechanisms and therapeutic potential"],"prefix":"10.1038","volume":"11","author":[{"given":"Minmin","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7206-7277","authenticated-orcid":false,"given":"Shuang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2204-5042","authenticated-orcid":false,"given":"Desheng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2354-5321","authenticated-orcid":false,"given":"Yongguang","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"2810_CR1","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","volume":"30","author":"X He","year":"2020","unstructured":"He, X. & Xu, C. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 30, 660\u2013669 (2020).","journal-title":"Cell Res."},{"key":"2810_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252\u2013264 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"2810_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.canlet.2016.01.043","volume":"387","author":"T Wu","year":"2017","unstructured":"Wu, T. & Dai, Y. Tumor microenvironment and therapeutic response. Cancer Lett. 387, 61\u201368 (2017).","journal-title":"Cancer Lett."},{"key":"2810_CR4","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow, A., Perica, K., Klebanoff, C. A. & Wolchok, J. D. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat. Rev. Clin. Oncol. 19, 775\u2013790 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2810_CR5","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad, G., Helmink, B. A., Sharma, P. & Wargo, J. A. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 184, 5309\u20135337 (2021).","journal-title":"Cell"},{"key":"2810_CR6","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/s41573-021-00155-y","volume":"20","author":"SP Kubli","year":"2021","unstructured":"Kubli, S. P. et al. Beyond immune checkpoint blockade: emerging immunological strategies. Nat. Rev. Drug Discov. 20, 899\u2013919 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2810_CR7","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","volume":"40","author":"H Zhang","year":"2021","unstructured":"Zhang, H. et al. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J. Exp. Clin. Cancer Res. 40, 184 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2810_CR8","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s13046-018-0937-6","volume":"37","author":"A Rotte","year":"2018","unstructured":"Rotte, A., D\u2019Orazi, G. & Bhandaru, M. J. Exp. Clin. Cancer Res. 37, 262 (2018).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2810_CR9","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41590-023-01569-z","volume":"24","author":"V Aggarwal","year":"2023","unstructured":"Aggarwal, V., Workman, C. J. & Vignali, D. A. A. LAG-3 as the third checkpoint inhibitor. Nat. Immunol. 24, 1415\u20131422 (2023).","journal-title":"Nat. Immunol."},{"key":"2810_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai, L. et al. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J. Hematol. Oncol. 16, 101 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"2810_CR11","doi-asserted-by":"publisher","first-page":"eadf2223","DOI":"10.1126\/sciimmunol.adf2223","volume":"9","author":"KO Dixon","year":"2024","unstructured":"Dixon, K. O., Lahore, G. F. & Kuchroo, V. K. Beyond T cell exhaustion: TIM-3 regulation of myeloid cells. Sci. Immunol. 9, eadf2223 (2024).","journal-title":"Sci. Immunol."},{"key":"2810_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-021-01056-8","volume":"14","author":"JA Marin-Acevedo","year":"2021","unstructured":"Marin-Acevedo, J. A., Kimbrough, E. O. & Lou, Y. Next generation of immune checkpoint inhibitors and beyond. J. Hematol. Oncol. 14, 45 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"2810_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2020.574111","volume":"8","author":"A Budreviciute","year":"2020","unstructured":"Budreviciute, A. et al. Management and prevention strategies for non-communicable diseases (NCDs) and their risk factors. Front. Public Health 8, 574111 (2020).","journal-title":"Front. Public Health"},{"key":"2810_CR14","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1152\/physrev.00033.2011","volume":"93","author":"A Tchernof","year":"2013","unstructured":"Tchernof, A. & Despr\u00e9s, J. P. Pathophysiology of human visceral obesity: an update. Physiol. Rev. 93, 359\u2013404 (2013).","journal-title":"Physiol. Rev."},{"key":"2810_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.4158\/EP.7.1.44","volume":"7","author":"G Boden","year":"2001","unstructured":"Boden, G. Free fatty acids\u2014the link between obesity and insulin resistance. Endocr. Pract. 7, 44\u201351 (2001).","journal-title":"Endocr. Pract."},{"key":"2810_CR16","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1161\/CIRCRESAHA.115.306825","volume":"118","author":"SN Bhupathiraju","year":"2016","unstructured":"Bhupathiraju, S. N. & Hu, F. B. Epidemiology of obesity and diabetes and their cardiovascular complications. Circ. Res. 118, 1723\u20131735 (2016).","journal-title":"Circ. Res."},{"key":"2810_CR17","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/ATVBAHA.117.310221","volume":"38","author":"AM Schmidt","year":"2018","unstructured":"Schmidt, A. M. Highlighting diabetes mellitus: the epidemic continues. Arterioscler. Thromb. Vasc. Biol. 38, e1\u2013e8 (2018).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2810_CR18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2400385121","volume":"121","author":"W Du","year":"2024","unstructured":"Du, W. et al. The microbiota-dependent tryptophan metabolite alleviates high-fat diet-induced insulin resistance through the hepatic AhR\/TSC2\/mTORC1 axis. Proc. Natl. Acad. Sci. USA 121, e2400385121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2810_CR19","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1161\/CIRCULATIONAHA.106.678326","volume":"116","author":"I Klein","year":"2007","unstructured":"Klein, I. & Danzi, S. Thyroid disease and the heart. Circulation 116, 1725\u20131735 (2007).","journal-title":"Circulation"},{"key":"2810_CR20","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1016\/j.jacc.2013.11.004","volume":"63","author":"MD Jensen","year":"2014","unstructured":"Jensen, M. D. et al. 2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J. Am. Coll. Cardiol. 63, 2985\u20133023 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2810_CR21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S2213-8587(21)00245-X","volume":"10","author":"A Ceriello","year":"2022","unstructured":"Ceriello, A. et al. Glycaemic management in diabetes: old and new approaches. Lancet Diab. Endocrinol. 10, 75\u201384 (2022).","journal-title":"Lancet Diab. Endocrinol."},{"key":"2810_CR22","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/thy.2016.0229","volume":"26","author":"DS Ross","year":"2016","unstructured":"Ross, D. S. et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26, 1343\u20131421 (2016).","journal-title":"Thyroid"},{"key":"2810_CR23","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.soard.2012.07.010","volume":"9","author":"RW O\u2019Rourke","year":"2013","unstructured":"O\u2019Rourke, R. W. Inflammation, obesity, and the promise of immunotherapy for metabolic disease. Surg. Obes. Relat. Dis. 9, 609\u2013616 (2013).","journal-title":"Surg. Obes. Relat. Dis."},{"key":"2810_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202301019","volume":"19","author":"L Wang","year":"2023","unstructured":"Wang, L. et al. Engineered cytokine-primed extracellular vesicles with high PD-L1 expression ameliorate type 1 diabetes. Small 19, e2301019 (2023).","journal-title":"Small"},{"key":"2810_CR25","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/2201352a0","volume":"220","author":"I Hellstr\u00f6m","year":"1968","unstructured":"Hellstr\u00f6m, I., Hellstr\u00f6m, K. E., Pierce, G. E. & Yang, J. P. Cellular and humoral immunity to different types of human neoplasms. Nature 220, 1352\u20131354 (1968).","journal-title":"Nature"},{"key":"2810_CR26","doi-asserted-by":"publisher","first-page":"5340","DOI":"10.1073\/pnas.96.10.5340","volume":"96","author":"DM Pardoll","year":"1999","unstructured":"Pardoll, D. M. Inducing autoimmune disease to treat cancer. Proc. Natl. Acad. Sci. USA 96, 5340\u20135342 (1999).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2810_CR27","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S0065-2776(06)90008-X","volume":"90","author":"AJ Korman","year":"2006","unstructured":"Korman, A. J., Peggs, K. S. & Allison, J. P. Checkpoint blockade in cancer immunotherapy. Adv. Immunol. 90, 297\u2013339 (2006).","journal-title":"Adv. Immunol."},{"key":"2810_CR28","doi-asserted-by":"publisher","first-page":"eaax0182","DOI":"10.1126\/science.aax0182","volume":"367","author":"SL Topalian","year":"2020","unstructured":"Topalian, S. L., Taube, J. M. & Pardoll, D. M. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science 367, eaax0182 (2020).","journal-title":"Science"},{"key":"2810_CR29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.semcancer.2022.03.014","volume":"86","author":"S Gaikwad","year":"2022","unstructured":"Gaikwad, S. et al. Immune checkpoint proteins: signaling mechanisms and molecular interactions in cancer immunotherapy. Semin. Cancer Biol. 86, 137\u2013150 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"2810_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.70196","volume":"13","author":"E Rezazadeh-Gavgani","year":"2025","unstructured":"Rezazadeh-Gavgani, E. et al. Immune checkpoint molecules: a review on pathways and immunotherapy implications. Immun. Inflamm. Dis. 13, e70196 (2025).","journal-title":"Immun. Inflamm. Dis."},{"key":"2810_CR31","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.semcancer.2022.02.019","volume":"86","author":"AF Haddad","year":"2022","unstructured":"Haddad, A. F., Young, J. S., Gill, S. & Aghi, M. K. Resistance to immune checkpoint blockade: mechanisms, counter-acting approaches, and future directions. Semin. Cancer Biol. 86, 532\u2013541 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"2810_CR32","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","volume":"11","author":"Y Ishida","year":"1992","unstructured":"Ishida, Y., Agata, Y., Shibahara, K. & Honjo, T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11, 3887\u20133895 (1992).","journal-title":"EMBO J."},{"key":"2810_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02023-w","volume":"23","author":"X Lin","year":"2024","unstructured":"Lin, X. et al. Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol. Cancer 23, 108 (2024).","journal-title":"Mol. Cancer"},{"key":"2810_CR34","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S0968-0004(03)00091-4","volume":"28","author":"BG Neel","year":"2003","unstructured":"Neel, B. G., Gu, H. & Pao, L. The \u2018Shp\u2019ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem. Sci. 28, 284\u2013293 (2003).","journal-title":"Trends Biochem. Sci."},{"key":"2810_CR35","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","volume":"131","author":"ZY Xu-Monette","year":"2018","unstructured":"Xu-Monette, Z. Y., Zhou, J. & Young, K. H. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood 131, 68\u201383 (2018).","journal-title":"Blood"},{"key":"2810_CR36","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.add4947","volume":"8","author":"K Suzuki","year":"2023","unstructured":"Suzuki, K. et al. Anti-PD-1 antibodies recognizing the membrane-proximal region are PD-1 agonists that can down-regulate inflammatory diseases. Sci. Immunol. 8, eadd4947 (2023).","journal-title":"Sci. Immunol."},{"key":"2810_CR37","first-page":"60","volume":"75","author":"S Ozsoylu","year":"1986","unstructured":"Ozsoylu, S. Lymphocyte subpopulations in sickle-cell anemia. Acta Haematol. 75, 60 (1986).","journal-title":"Acta Haematol."},{"key":"2810_CR38","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/70932","volume":"5","author":"H Dong","year":"1999","unstructured":"Dong, H., Zhu, G., Tamada, K. & Chen, L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 5, 1365\u20131369 (1999).","journal-title":"Nat. Med."},{"key":"2810_CR39","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027\u20131034 (2000).","journal-title":"J. Exp. Med."},{"key":"2810_CR40","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/ni1443","volume":"8","author":"AH Sharpe","year":"2007","unstructured":"Sharpe, A. H., Wherry, E. J., Ahmed, R. & Freeman, G. J. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 8, 239\u2013245 (2007).","journal-title":"Nat. Immunol."},{"key":"2810_CR41","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.molmed.2014.10.009","volume":"21","author":"KC Ohaegbulam","year":"2015","unstructured":"Ohaegbulam, K. C. et al. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol. Med. 21, 24\u201333 (2015).","journal-title":"Trends Mol. Med."},{"key":"2810_CR42","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","volume":"2","author":"L Vanhersecke","year":"2021","unstructured":"Vanhersecke, L. et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat. Cancer 2, 794\u2013802 (2021).","journal-title":"Nat. Cancer"},{"key":"2810_CR43","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMra1514296","volume":"375","author":"VA Boussiotis","year":"2016","unstructured":"Boussiotis, V. A. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N. Engl. J. Med. 375, 1767\u20131778 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2810_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18298-8","volume":"11","author":"DH Peng","year":"2020","unstructured":"Peng, D. H. et al. Collagen promotes anti-PD-1\/PD-L1 resistance in cancer through LAIR1-dependent CD8(+) T cell exhaustion. Nat. Commun. 11, 4520 (2020).","journal-title":"Nat. Commun."},{"key":"2810_CR45","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe, A. H. & Pauken, K. E. The diverse functions of the PD1 inhibitory pathway. Nat. Rev. Immunol. 18, 153\u2013167 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"2810_CR46","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-018-0756-0","volume":"564","author":"X Meng","year":"2018","unstructured":"Meng, X. et al. FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells. Nature 564, 130\u2013135 (2018).","journal-title":"Nature"},{"key":"2810_CR47","doi-asserted-by":"publisher","first-page":"28239","DOI":"10.1073\/pnas.2004570117","volume":"117","author":"XA Zhou","year":"2020","unstructured":"Zhou, X. A. et al. KLHL22 maintains PD-1 homeostasis and prevents excessive T cell suppression. Proc. Natl. Acad. Sci. USA 117, 28239\u201328250 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2810_CR48","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","volume":"48","author":"C Sun","year":"2018","unstructured":"Sun, C., Mezzadra, R. & Schumacher, T. N. Regulation and function of the PD-L1 checkpoint. Immunity 48, 434\u2013452 (2018).","journal-title":"Immunity"},{"key":"2810_CR49","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","volume":"76","author":"JH Cha","year":"2019","unstructured":"Cha, J. H. et al. Mechanisms controlling PD-L1 expression in cancer. Mol. Cell 76, 359\u2013370 (2019).","journal-title":"Mol. Cell"},{"key":"2810_CR50","volume":"10","author":"Z Ye","year":"2023","unstructured":"Ye, Z. et al. Manipulation of PD-L1 endosomal trafficking promotes anticancer immunity. Adv. Sci. (Weinh.) 10, e2206411 (2023).","journal-title":"Adv. Sci. (Weinh.)"},{"key":"2810_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi, M. et al. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol. Cancer 21, 28 (2022).","journal-title":"Mol. Cancer"},{"key":"2810_CR52","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/imm.12788","volume":"152","author":"T Jelinek","year":"2017","unstructured":"Jelinek, T. et al. PD-1\/PD-L1 inhibitors in haematological malignancies: update 2017. Immunology 152, 357\u2013371 (2017).","journal-title":"Immunology"},{"key":"2810_CR53","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41392-023-01605-2","volume":"8","author":"ZW Huang","year":"2023","unstructured":"Huang, Z. W. et al. STAT5 promotes PD-L1 expression by facilitating histone lactylation to drive immunosuppression in acute myeloid leukemia. Signal Transduct. Target. Ther. 8, 391 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2810_CR54","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/21645515.2019.1571892","volume":"15","author":"Y Jiang","year":"2019","unstructured":"Jiang, Y., Chen, M., Nie, H. & Yuan, Y. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum. Vaccin. Immunother. 15, 1111\u20131122 (2019).","journal-title":"Hum. Vaccin. Immunother."},{"key":"2810_CR55","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1634\/theoncologist.2019-IO-S1-s05","volume":"24","author":"L Xia","year":"2019","unstructured":"Xia, L., Liu, Y. & Wang, Y. PD-1\/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions. Oncologist 24, S31\u2013s41 (2019).","journal-title":"Oncologist"},{"key":"2810_CR56","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s11899-020-00589-y","volume":"15","author":"W Xie","year":"2020","unstructured":"Xie, W. et al. PD-1\/PD-L1 pathway and its blockade in patients with classic Hodgkin lymphoma and non-Hodgkin large-cell lymphomas. Curr. Hematol. Malig. Rep. 15, 372\u2013381 (2020).","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"2810_CR57","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.21.02508","volume":"41","author":"KJ Harrington","year":"2023","unstructured":"Harrington, K. J. et al. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the Phase III KEYNOTE-048 study. J. Clin. Oncol. 41, 790\u2013802 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2810_CR58","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40265-022-01723-1","volume":"82","author":"J Paik","year":"2022","unstructured":"Paik, J. Nivolumab plus relatlimab: first approval. Drugs 82, 925\u2013931 (2022).","journal-title":"Drugs"},{"key":"2810_CR59","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894\u20131905 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2810_CR60","doi-asserted-by":"publisher","first-page":"e002500","DOI":"10.1136\/jitc-2021-002500","volume":"10","author":"M Bajor","year":"2022","unstructured":"Bajor, M. et al. PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells. J. Immunother. Cancer 10, e002500 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"2810_CR61","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cellimm.2016.09.009","volume":"310","author":"MR Zamani","year":"2016","unstructured":"Zamani, M. R. et al. PD-1\/PD-L and autoimmunity: a growing relationship. Cell. Immunol. 310, 27\u201341 (2016).","journal-title":"Cell. Immunol."},{"key":"2810_CR62","doi-asserted-by":"publisher","first-page":"eaav7431","DOI":"10.1126\/scitranslmed.aav7431","volume":"12","author":"M Mayoux","year":"2020","unstructured":"Mayoux, M. et al. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Sci. Transl. Med. 12, eaav7431 (2020).","journal-title":"Sci. Transl. Med."},{"key":"2810_CR63","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1001\/jamaoncol.2019.5367","volume":"6","author":"J Duan","year":"2020","unstructured":"Duan, J. et al. Use of immunotherapy with programmed cell death 1 vs. programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis. JAMA Oncol. 6, 375\u2013384 (2020).","journal-title":"JAMA Oncol."},{"key":"2810_CR64","doi-asserted-by":"publisher","first-page":"Itc17","DOI":"10.7326\/AITC202402200","volume":"177","author":"M Ramos-Casals","year":"2024","unstructured":"Ramos-Casals, M. & Sis\u00f3-Almirall, A. Immune-related adverse events of immune checkpoint inhibitors. Ann. Intern. Med. 177, Itc17\u2013itc32 (2024).","journal-title":"Ann. Intern. Med."},{"key":"2810_CR65","doi-asserted-by":"publisher","first-page":"e006570","DOI":"10.1136\/jitc-2022-006570","volume":"11","author":"JI Caulfield","year":"2023","unstructured":"Caulfield, J. I. et al. Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors. J. Immunother. Cancer 11, e006570 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"2810_CR66","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/jamacardio.2021.2241","volume":"6","author":"LH Lehmann","year":"2021","unstructured":"Lehmann, L. H. et al. Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis: a narrative review. JAMA Cardiol. 6, 1329\u20131337 (2021).","journal-title":"JAMA Cardiol."},{"key":"2810_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41401-020-0366-x","volume":"42","author":"Q Wu","year":"2021","unstructured":"Wu, Q. et al. Small molecule inhibitors targeting the PD-1\/PD-L1 signaling pathway. Acta Pharm. Sin. 42, 1\u20139 (2021).","journal-title":"Acta Pharm. Sin."},{"key":"2810_CR68","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/328267a0","volume":"328","author":"JF Brunet","year":"1987","unstructured":"Brunet, J. F. et al. A new member of the immunoglobulin superfamily\u2014CTLA-4. Nature 328, 267\u2013270 (1987).","journal-title":"Nature"},{"key":"2810_CR69","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/978-981-15-3266-5_2","volume":"1248","author":"S Van Coillie","year":"2020","unstructured":"Van Coillie, S., Wiernicki, B. & Xu, J. Molecular and cellular functions of CTLA-4. Adv. Exp. Med. Biol. 1248, 7\u201332 (2020).","journal-title":"Adv. Exp. Med. Biol."},{"key":"2810_CR70","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S1074-7613(00)80480-X","volume":"4","author":"PS Linsley","year":"1996","unstructured":"Linsley, P. S. et al. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity 4, 535\u2013543 (1996).","journal-title":"Immunity"},{"key":"2810_CR71","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","volume":"131","author":"B Rowshanravan","year":"2018","unstructured":"Rowshanravan, B., Halliday, N. & Sansom, D. M. CTLA-4: a moving target in immunotherapy. Blood 131, 58\u201367 (2018).","journal-title":"Blood"},{"key":"2810_CR72","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1751-2980.2010.00462.x","volume":"11","author":"T Jiang","year":"2010","unstructured":"Jiang, T. et al. Effect of cytotoxic T lymphocyte-associated molecule 4 1661 gene polymorphism on its expression and transcription in ulcerative colitis. J. Dig. Dis. 11, 369\u2013375 (2010).","journal-title":"J. Dig. Dis."},{"key":"2810_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1091-2","volume":"18","author":"S Qin","year":"2019","unstructured":"Qin, S. et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol. Cancer 18, 155 (2019).","journal-title":"Mol. Cancer"},{"key":"2810_CR74","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1097\/CM9.0000000000001082","volume":"133","author":"HH Zhu","year":"2020","unstructured":"Zhu, H. H., Feng, Y. & Hu, X. S. Emerging immunotherapy targets in lung cancer. Chin. Med. J. (Engl.) 133, 2456\u20132465 (2020).","journal-title":"Chin. Med. J. (Engl.)"},{"key":"2810_CR75","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/cr.2016.151","volume":"27","author":"A Tanaka","year":"2017","unstructured":"Tanaka, A. & Sakaguchi, S. Regulatory T cells in cancer immunotherapy. Cell Res. 27, 109\u2013118 (2017).","journal-title":"Cell Res."},{"key":"2810_CR76","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1126\/science.1202947","volume":"332","author":"OS Qureshi","year":"2011","unstructured":"Qureshi, O. S. et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332, 600\u2013603 (2011).","journal-title":"Science"},{"key":"2810_CR77","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/s41573-020-0081-9","volume":"19","author":"NM Edner","year":"2020","unstructured":"Edner, N. M., Carlesso, G., Rush, J. S. & Walker, L. S. K. Targeting co-stimulatory molecules in autoimmune disease. Nat. Rev. Drug Discov. 19, 860\u2013883 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2810_CR78","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer, A. et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389, 255\u2013265 (2017).","journal-title":"Lancet"},{"key":"2810_CR79","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711\u2013723 (2010).","journal-title":"N. Engl. J. Med."},{"key":"2810_CR80","doi-asserted-by":"crossref","unstructured":"in Cancer Discov Vol. 9 569\u2013570 (\u00a92019 American Association for Cancer Research, 2019).","DOI":"10.1158\/2159-8290.CD-NB2019-039"},{"key":"2810_CR81","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1073\/pnas.0712237105","volume":"105","author":"FS Hodi","year":"2008","unstructured":"Hodi, F. S. et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc. Natl. Acad. Sci. USA 105, 3005\u20133010 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2810_CR82","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1200\/JCO.22.00975","volume":"41","author":"ML Johnson","year":"2023","unstructured":"Johnson, M. L. et al. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the Phase III POSEIDON study. J. Clin. Oncol. 41, 1213\u20131227 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2810_CR83","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","volume":"13","author":"C Boutros","year":"2016","unstructured":"Boutros, C. et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat. Rev. Clin. Oncol. 13, 473\u2013486 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2810_CR84","doi-asserted-by":"publisher","first-page":"7276","DOI":"10.1158\/0008-5472.CAN-05-2128","volume":"66","author":"E Kocak","year":"2006","unstructured":"Kocak, E. et al. Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res. 66, 7276\u20137284 (2006).","journal-title":"Cancer Res."},{"key":"2810_CR85","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","volume":"17","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi, L. et al. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat. Rev. Clin. Oncol. 17, 725\u2013741 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2810_CR86","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41590-022-01176-4","volume":"23","author":"C Guy","year":"2022","unstructured":"Guy, C. et al. LAG3 associates with TCR-CD3 complexes and suppresses signaling by driving co-receptor-Lck dissociation. Nat. Immunol. 23, 757\u2013767 (2022).","journal-title":"Nat. Immunol."},{"key":"2810_CR87","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/s41590-019-0512-0","volume":"20","author":"LP Andrews","year":"2019","unstructured":"Andrews, L. P., Yano, H. & Vignali, D. A. A. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat. Immunol. 20, 1425\u20131434 (2019).","journal-title":"Nat. Immunol."},{"key":"2810_CR88","first-page":"451","volume":"21","author":"X Kong","year":"2024","unstructured":"Kong, X. et al. Immune checkpoint inhibitors: breakthroughs in cancer treatment. Cancer Biol. Med. 21, 451\u2013472 (2024).","journal-title":"Cancer Biol. Med."},{"key":"2810_CR89","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1084\/jem.171.5.1393","volume":"171","author":"F Triebel","year":"1990","unstructured":"Triebel, F. et al. LAG-3, a novel lymphocyte activation gene closely related to CD4. J. Exp. Med. 171, 1393\u20131405 (1990).","journal-title":"J. Exp. Med."},{"key":"2810_CR90","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.immuni.2018.07.007","volume":"49","author":"D Bauch\u00e9","year":"2018","unstructured":"Bauch\u00e9, D. et al. LAG3(+) regulatory T cells restrain interleukin-23-producing CX3CR1(+) gut-resident macrophages during Group 3 innate lymphoid cell-driven colitis. Immunity 49, 342\u2013352.e345 (2018).","journal-title":"Immunity"},{"key":"2810_CR91","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.785091","volume":"12","author":"AP Shi","year":"2021","unstructured":"Shi, A. P. et al. Immune checkpoint LAG3 and its ligand FGL1 in cancer. Front. Immunol. 12, 785091 (2021).","journal-title":"Front. Immunol."},{"key":"2810_CR92","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1158\/0008-5472.CAN-13-2690","volume":"74","author":"F Xu","year":"2014","unstructured":"Xu, F. et al. LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses. Cancer Res. 74, 3418\u20133428 (2014).","journal-title":"Cancer Res."},{"key":"2810_CR93","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41375-021-01301-6","volume":"36","author":"J Bae","year":"2022","unstructured":"Bae, J. et al. Targeting LAG3\/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma. Leukemia 36, 138\u2013154 (2022).","journal-title":"Leukemia"},{"key":"2810_CR94","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/eji.200323382","volume":"33","author":"CJ Workman","year":"2003","unstructured":"Workman, C. J. & Vignali, D. A. The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. Eur. J. Immunol. 33, 970\u2013979 (2003).","journal-title":"Eur. J. Immunol."},{"key":"2810_CR95","doi-asserted-by":"publisher","first-page":"6017","DOI":"10.1074\/jbc.RA119.007455","volume":"294","author":"TK Maeda","year":"2019","unstructured":"Maeda, T. K. et al. Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3 inhibit T cell activation. J. Biol. Chem. 294, 6017\u20136026 (2019).","journal-title":"J. Biol. Chem."},{"key":"2810_CR96","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1002\/1521-4141(2001010)31:10<2885::AID-IMMU2885>3.0.CO;2-2","volume":"31","author":"N Iouzalen","year":"2001","unstructured":"Iouzalen, N., Andreae, S., Hannier, S. & Triebel, F. L. A. P. A lymphocyte activation gene-3 (LAG-3)-associated protein that binds to a repeated EP motif in the intracellular region of LAG-3, may participate in the down-regulation of the CD3\/TCR activation pathway. Eur. J. Immunol. 31, 2885\u20132891 (2001).","journal-title":"Eur. J. Immunol."},{"key":"2810_CR97","doi-asserted-by":"publisher","first-page":"e2011196118","DOI":"10.1073\/pnas.2011196118","volume":"118","author":"S Zhang","year":"2021","unstructured":"Zhang, S. et al. Mechanistic basis for receptor-mediated pathological \u03b1-synuclein fibril cell-to-cell transmission in Parkinson\u2019s disease. Proc. Natl. Acad. Sci. USA 118, e2011196118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2810_CR98","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/415536a","volume":"415","author":"L Monney","year":"2002","unstructured":"Monney, L. et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415, 536\u2013541 (2002).","journal-title":"Nature"},{"key":"2810_CR99","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1002\/eji.200939274","volume":"39","author":"WD Hastings","year":"2009","unstructured":"Hastings, W. D. et al. TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines. Eur. J. Immunol. 39, 2492\u20132501 (2009).","journal-title":"Eur. J. Immunol."},{"key":"2810_CR100","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/ni987","volume":"4","author":"A S\u00e1nchez-Fueyo","year":"2003","unstructured":"S\u00e1nchez-Fueyo, A. et al. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat. Immunol. 4, 1093\u20131101 (2003).","journal-title":"Nat. Immunol."},{"key":"2810_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21099-2","volume":"12","author":"R Yang","year":"2021","unstructured":"Yang, R. et al. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat. Commun. 12, 832 (2021).","journal-title":"Nat. Commun."},{"key":"2810_CR102","doi-asserted-by":"publisher","first-page":"106826","DOI":"10.1016\/j.biocel.2025.106826","volume":"186","author":"A Manzoor","year":"2025","unstructured":"Manzoor, A. & Barakat, K. Therapeutic potential of TIM-3 inhibition in cancer, viral infections, and autoimmune disorders. Int. J. Biochem. Cell Biol. 186, 106826 (2025).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"2810_CR103","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.immuni.2007.01.016","volume":"26","author":"E Cao","year":"2007","unstructured":"Cao, E. et al. T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface. Immunity 26, 311\u2013321 (2007).","journal-title":"Immunity"},{"key":"2810_CR104","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.3748\/wjg.v22.i7.2294","volume":"22","author":"Y Liu","year":"2016","unstructured":"Liu, Y., Gao, L. F., Liang, X. H. & Ma, C. H. Role of Tim-3 in hepatitis B virus infection: an overview. World J. Gastroenterol. 22, 2294\u20132303 (2016).","journal-title":"World J. Gastroenterol."},{"key":"2810_CR105","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41423-018-0032-0","volume":"16","author":"X Du","year":"2019","unstructured":"Du, X. et al. Increased Tim-3 expression alleviates liver injury by regulating macrophage activation in MCD-induced NASH mice. Cell. Mol. Immunol. 16, 878\u2013886 (2019).","journal-title":"Cell. Mol. Immunol."},{"key":"2810_CR106","doi-asserted-by":"publisher","first-page":"17858","DOI":"10.1073\/pnas.0903474106","volume":"106","author":"N Stanietsky","year":"2009","unstructured":"Stanietsky, N. et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc. Natl. Acad. Sci. USA 106, 17858\u201317863 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2810_CR107","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/eji.200839116","volume":"39","author":"KS Boles","year":"2009","unstructured":"Boles, K. S. et al. A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC. Eur. J. Immunol. 39, 695\u2013703 (2009).","journal-title":"Eur. J. Immunol."},{"key":"2810_CR108","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ni.1674","volume":"10","author":"X Yu","year":"2009","unstructured":"Yu, X. et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat. Immunol. 10, 48\u201357 (2009).","journal-title":"Nat. Immunol."},{"key":"2810_CR109","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.immuni.2022.02.005","volume":"55","author":"KL Banta","year":"2022","unstructured":"Banta, K. L. et al. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8(+) T cell responses. Immunity 55, 512\u2013526.e519 (2022).","journal-title":"Immunity"},{"key":"2810_CR110","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1007\/s00262-018-2246-5","volume":"67","author":"BL Solomon","year":"2018","unstructured":"Solomon, B. L. & Garrido-Laguna, I. TIGIT: a novel immunotherapy target moving from bench to bedside. Cancer Immunol. Immunother. 67, 1659\u20131667 (2018).","journal-title":"Cancer Immunol. Immunother."},{"key":"2810_CR111","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/cei.13407","volume":"200","author":"H Harjunp\u00e4\u00e4","year":"2020","unstructured":"Harjunp\u00e4\u00e4, H. & Guillerey, C. TIGIT as an emerging immune checkpoint. Clin. Exp. Immunol. 200, 108\u2013119 (2020).","journal-title":"Clin. Exp. Immunol."},{"key":"2810_CR112","first-page":"127","volume":"410","author":"N Joller","year":"2017","unstructured":"Joller, N. & Kuchroo, V. K. Tim-3, Lag-3, and TIGIT. Curr. Top. Microbiol. Immunol. 410, 127\u2013156 (2017).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"2810_CR113","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.4049\/jimmunol.1003081","volume":"186","author":"N Joller","year":"2011","unstructured":"Joller, N. et al. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J. Immunol. 186, 1338\u20131342 (2011).","journal-title":"J. Immunol."},{"key":"2810_CR114","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.4049\/jimmunol.1103627","volume":"188","author":"E Lozano","year":"2012","unstructured":"Lozano, E., Dominguez-Villar, M., Kuchroo, V. & Hafler, D. A. The TIGIT\/CD226 axis regulates human T cell function. J. Immunol. 188, 3869\u20133875 (2012).","journal-title":"J. Immunol."},{"key":"2810_CR115","doi-asserted-by":"publisher","first-page":"10277","DOI":"10.1073\/pnas.0805458105","volume":"105","author":"KA Hofmeyer","year":"2008","unstructured":"Hofmeyer, K. A., Ray, A. & Zang, X. The contrasting role of B7-H3. Proc. Natl. Acad. Sci. USA 105, 10277\u201310278 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2810_CR116","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nri3701","volume":"14","author":"KN Pollizzi","year":"2014","unstructured":"Pollizzi, K. N. & Powell, J. D. Integrating canonical and metabolic signalling programmes in the regulation of T cell responses. Nat. Rev. Immunol. 14, 435\u2013446 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"2810_CR117","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/ni1144","volume":"6","author":"JR Sedy","year":"2005","unstructured":"Sedy, J. R. et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat. Immunol. 6, 90\u201398 (2005).","journal-title":"Nat. Immunol."},{"key":"2810_CR118","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1126\/science.2326636","volume":"248","author":"S Kovats","year":"1990","unstructured":"Kovats, S. et al. A class I antigen, HLA-G, expressed in human trophoblasts. Science 248, 220\u2013223 (1990).","journal-title":"Science"},{"key":"2810_CR119","doi-asserted-by":"publisher","first-page":"11520","DOI":"10.1073\/pnas.94.21.11520","volume":"94","author":"N Rouas-Freiss","year":"1997","unstructured":"Rouas-Freiss, N. et al. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc. Natl. Acad. Sci. USA 94, 11520\u201311525 (1997).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2810_CR120","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","volume":"52","author":"MEW Logtenberg","year":"2020","unstructured":"Logtenberg, M. E. W., Scheeren, F. A. & Schumacher, T. N. The CD47-SIRP\u03b1 immune checkpoint. Immunity 52, 742\u2013752 (2020).","journal-title":"Immunity"},{"key":"2810_CR121","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.it.2017.12.005","volume":"39","author":"A Veillette","year":"2018","unstructured":"Veillette, A. & Chen, J. SIRP\u03b1-CD47 immune checkpoint blockade in anticancer therapy. Trends Immunol. 39, 173\u2013184 (2018).","journal-title":"Trends Immunol."},{"key":"2810_CR122","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/BS9.0000000000000109","volume":"4","author":"T Yang","year":"2022","unstructured":"Yang, T. et al. LILRB4, an immune checkpoint on myeloid cells. Blood Sci. 4, 49\u201356 (2022).","journal-title":"Blood Sci."},{"key":"2810_CR123","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cmet.2015.12.015","volume":"23","author":"J Font-Burgada","year":"2016","unstructured":"Font-Burgada, J., Sun, B. & Karin, M. Obesity and cancer: the oil that feeds the flame. Cell Metab. 23, 48\u201362 (2016).","journal-title":"Cell Metab."},{"key":"2810_CR124","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ccr.2014.07.001","volume":"26","author":"H Nakagawa","year":"2014","unstructured":"Nakagawa, H. et al. ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. Cancer Cell 26, 331\u2013343 (2014).","journal-title":"Cancer Cell"},{"key":"2810_CR125","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1093\/advances\/nmy055","volume":"10","author":"B Caballero","year":"2019","unstructured":"Caballero, B. Humans against obesity: who will win? Adv. Nutr. 10, S4\u2013s9 (2019).","journal-title":"Adv. Nutr."},{"key":"2810_CR126","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s00292-020-00782-z","volume":"41","author":"P Fischer-Posovszky","year":"2020","unstructured":"Fischer-Posovszky, P. & M\u00f6ller, P. [The immune system of adipose tissue: obesity-associated inflammation]. Pathologe 41, 224\u2013229 (2020).","journal-title":"Pathologe"},{"key":"2810_CR127","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.it.2019.07.006","volume":"40","author":"H Kane","year":"2019","unstructured":"Kane, H. & Lynch, L. Innate immune control of adipose tissue homeostasis. Trends Immunol. 40, 857\u2013872 (2019).","journal-title":"Trends Immunol."},{"key":"2810_CR128","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1172\/JCI29881","volume":"117","author":"CN Lumeng","year":"2007","unstructured":"Lumeng, C. N., Bodzin, J. L. & Saltiel, A. R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Investig. 117, 175\u2013184 (2007).","journal-title":"J. Clin. Investig."},{"key":"2810_CR129","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/nm.1964","volume":"15","author":"S Nishimura","year":"2009","unstructured":"Nishimura, S. et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat. Med. 15, 914\u2013920 (2009).","journal-title":"Nat. Med."},{"key":"2810_CR130","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.3389\/fimmu.2019.01173","volume":"10","author":"J Lu","year":"2019","unstructured":"Lu, J., Zhao, J., Meng, H. & Zhang, X. Adipose tissue-resident immune cells in obesity and type 2 diabetes. Front. Immunol. 10, 1173 (2019).","journal-title":"Front. Immunol."},{"key":"2810_CR131","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/nm.2002","volume":"15","author":"M Feuerer","year":"2009","unstructured":"Feuerer, M. et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 15, 930\u2013939 (2009).","journal-title":"Nat. Med."},{"key":"2810_CR132","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/nm.2885","volume":"18","author":"S Talukdar","year":"2012","unstructured":"Talukdar, S. et al. Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. Nat. Med. 18, 1407\u20131412 (2012).","journal-title":"Nat. Med."},{"key":"2810_CR133","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/j.celrep.2018.10.091","volume":"25","author":"G Oldenhove","year":"2018","unstructured":"Oldenhove, G. et al. PD-1 is involved in the dysregulation of type 2 innate lymphoid cells in a murine model of obesity. Cell Rep. 25, 2053\u20132060.e2054 (2018).","journal-title":"Cell Rep."},{"key":"2810_CR134","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.immuni.2024.04.024","volume":"57","author":"J Sun","year":"2024","unstructured":"Sun, J. et al. Metabolic regulator LKB1 controls adipose tissue ILC2 PD-1 expression and mitochondrial homeostasis to prevent insulin resistance. Immunity 57, 1289\u20131305.e1289 (2024).","journal-title":"Immunity"},{"key":"2810_CR135","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj6879","volume":"14","author":"C Schwartz","year":"2022","unstructured":"Schwartz, C. et al. Innate PD-L1 limits T cell-mediated adipose tissue inflammation and ameliorates diet-induced obesity. Sci. Transl. Med. 14, eabj6879 (2022).","journal-title":"Sci. Transl. Med."},{"key":"2810_CR136","doi-asserted-by":"publisher","first-page":"eaam7543","DOI":"10.1126\/scitranslmed.aam7543","volume":"9","author":"M Ben Nasr","year":"2017","unstructured":"Ben Nasr, M. et al. PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes. Sci. Transl. Med. 9, eaam7543 (2017).","journal-title":"Sci. Transl. Med."},{"key":"2810_CR137","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.590568","volume":"11","author":"CT Le","year":"2020","unstructured":"Le, C. T. et al. PD-1 blockade reverses obesity-mediated T cell priming impairment. Front. Immunol. 11, 590568 (2020).","journal-title":"Front. Immunol."},{"key":"2810_CR138","doi-asserted-by":"publisher","first-page":"289645","DOI":"10.1155\/2010\/289645","volume":"2010","author":"R Monteiro","year":"2010","unstructured":"Monteiro, R. & Azevedo, I. Chronic inflammation in obesity and the metabolic syndrome. Mediat. Inflamm. 2010, 289645 (2010).","journal-title":"Mediat. Inflamm."},{"key":"2810_CR139","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1016\/j.apsb.2023.01.012","volume":"13","author":"X Jin","year":"2023","unstructured":"Jin, X. et al. Pathophysiology of obesity and its associated diseases. Acta Pharm. Sin. B 13, 2403\u20132424 (2023).","journal-title":"Acta Pharm. Sin. B"},{"key":"2810_CR140","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.semcancer.2025.03.001","volume":"112","author":"S Sagliocchi","year":"2025","unstructured":"Sagliocchi, S. et al. The impact of the tumor microenvironment in the dual burden of obesity-cancer link. Semin. Cancer Biol. 112, 36\u201342 (2025).","journal-title":"Semin. Cancer Biol."},{"key":"2810_CR141","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1146\/annurev-pathol-052016-100322","volume":"12","author":"S Affo","year":"2017","unstructured":"Affo, S., Yu, L. X. & Schwabe, R. F. The role of cancer-associated fibroblasts and fibrosis in liver cancer. Annu. Rev. Pathol. 12, 153\u2013186 (2017).","journal-title":"Annu. Rev. Pathol."},{"key":"2810_CR142","doi-asserted-by":"publisher","first-page":"E5900","DOI":"10.1073\/pnas.1706559114","volume":"114","author":"V Chew","year":"2017","unstructured":"Chew, V. et al. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proc. Natl. Acad. Sci. USA 114, E5900\u2013e5909 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2810_CR143","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1016\/j.cell.2020.11.009","volume":"183","author":"AE Ringel","year":"2020","unstructured":"Ringel, A. E. et al. Obesity shapes metabolism in the tumor microenvironment to suppress anti-tumor immunity. Cell 183, 1848\u20131866.e1826 (2020).","journal-title":"Cell"},{"key":"2810_CR144","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1056\/NEJMsr1606602","volume":"375","author":"B Lauby-Secretan","year":"2016","unstructured":"Lauby-Secretan, B. et al. Body fatness and cancer\u2013viewpoint of the IARC Working Group. N. Engl. J. Med. 375, 794\u2013798 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2810_CR145","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1001\/jamaoncol.2018.5639","volume":"5","author":"F Islami","year":"2019","unstructured":"Islami, F., Goding Sauer, A., Gapstur, S. M. & Jemal, A. Proportion of cancer cases attributable to excess body weight by US State, 2011\u20132015. JAMA Oncol. 5, 384\u2013392 (2019).","journal-title":"JAMA Oncol."},{"key":"2810_CR146","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47359-5","volume":"15","author":"A Piening","year":"2024","unstructured":"Piening, A. et al. Obesity-related T cell dysfunction impairs immunosurveillance and increases cancer risk. Nat. Commun. 15, 2835 (2024).","journal-title":"Nat. Commun."},{"key":"2810_CR147","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109285","volume":"35","author":"AK Pingili","year":"2021","unstructured":"Pingili, A. K. et al. Immune checkpoint blockade reprograms systemic immune landscape and tumor microenvironment in obesity-associated breast cancer. Cell Rep. 35, 109285 (2021).","journal-title":"Cell Rep."},{"key":"2810_CR148","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.cmet.2019.10.013","volume":"31","author":"C Zhang","year":"2020","unstructured":"Zhang, C. et al. STAT3 activation-induced fatty acid oxidation in CD8(+) T effector cells is critical for obesity-promoted breast tumor growth. Cell Metab. 31, 148\u2013161.e145 (2020).","journal-title":"Cell Metab."},{"key":"2810_CR149","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00799-8","volume":"8","author":"JR Ingram","year":"2017","unstructured":"Ingram, J. R. et al. PD-L1 is an activation-independent marker of brown adipocytes. Nat. Commun. 8, 647 (2017).","journal-title":"Nat. Commun."},{"key":"2810_CR150","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13046-020-01786-6","volume":"40","author":"W Fang","year":"2021","unstructured":"Fang, W. et al. Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8(+) T cell exclusion. J. Exp. Clin. Cancer Res. 40, 4 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2810_CR151","doi-asserted-by":"publisher","first-page":"e000964","DOI":"10.1136\/jitc-2020-000964","volume":"8","author":"B Wu","year":"2020","unstructured":"Wu, B. et al. Genetic ablation of adipocyte PD-L1 reduces tumor growth but accentuates obesity-associated inflammation. J. Immunother. Cancer 8, e000964 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"2810_CR152","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12929-022-00796-0","volume":"29","author":"JAF Assump\u00e7\u00e3o","year":"2022","unstructured":"Assump\u00e7\u00e3o, J. A. F. et al. The ambiguous role of obesity in oncology by promoting cancer but boosting antitumor immunotherapy. J. Biomed. Sci. 29, 12 (2022).","journal-title":"J. Biomed. Sci."},{"key":"2810_CR153","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40425-019-0527-y","volume":"7","author":"A Cortellini","year":"2019","unstructured":"Cortellini, A. et al. A multicenter study of body mass index in cancer patients treated with anti-PD-1\/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. J. Immunother. Cancer 7, 57 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"2810_CR154","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.1200\/JCO.2016.66.7311","volume":"34","author":"L Albiges","year":"2016","unstructured":"Albiges, L. et al. Body mass index and metastatic renal cell carcinoma: clinical and biological correlations. J. Clin. Oncol. 34, 3655\u20133663 (2016).","journal-title":"J. Clin. Oncol."},{"key":"2810_CR155","doi-asserted-by":"publisher","first-page":"e20210042","DOI":"10.1084\/jem.20210042","volume":"219","author":"L Dyck","year":"2022","unstructured":"Dyck, L. et al. Suppressive effects of the obese tumor microenvironment on CD8 T cell infiltration and effector function. J. Exp. Med. 219, e20210042 (2022).","journal-title":"J. Exp. Med."},{"key":"2810_CR156","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41591-018-0221-5","volume":"25","author":"Z Wang","year":"2019","unstructured":"Wang, Z. et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat. Med. 25, 141\u2013151 (2019).","journal-title":"Nat. Med."},{"key":"2810_CR157","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.4049\/jimmunol.2001152","volume":"207","author":"SO Dudzinski","year":"2021","unstructured":"Dudzinski, S. O. et al. Leptin augments antitumor immunity in obesity by repolarizing tumor-associated macrophages. J. Immunol. 207, 3122\u20133130 (2021).","journal-title":"J. Immunol."},{"key":"2810_CR158","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1756-9966-30-21","volume":"30","author":"F Amjadi","year":"2011","unstructured":"Amjadi, F. et al. Leptin promotes melanoma tumor growth in mice related to increasing circulating endothelial progenitor cells numbers and plasma NO production. J. Exp. Clin. Cancer Res. 30, 21 (2011).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2810_CR159","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s41586-024-07529-3","volume":"630","author":"JE Bader","year":"2024","unstructured":"Bader, J. E. et al. Obesity induces PD-1 on macrophages to suppress anti-tumour immunity. Nature 630, 968\u2013975 (2024).","journal-title":"Nature"},{"key":"2810_CR160","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.3390\/cells10092288","volume":"10","author":"T R\u00f6szer","year":"2021","unstructured":"R\u00f6szer, T. Adipose tissue immunometabolism and apoptotic cell clearance. Cells 10, 2288 (2021).","journal-title":"Cells"},{"key":"2810_CR161","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2219790120","volume":"120","author":"M Barends","year":"2023","unstructured":"Barends, M. et al. Dynamic interactome of the MHC I peptide loading complex in human dendritic cells. Proc. Natl. Acad. Sci. USA 120, e2219790120 (2023).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2810_CR162","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113984","volume":"385","author":"J Zheng","year":"2025","unstructured":"Zheng, J. et al. In situ antigen-capture strategies for enhancing dendritic cell-mediated anti-tumor immunity. J. Control Release 385, 113984 (2025).","journal-title":"J. Control Release"},{"key":"2810_CR163","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202207686","volume":"35","author":"J Yan","year":"2023","unstructured":"Yan, J. et al. Gold nanobipyramid-mediated apoptotic camouflage of adipocytes for obesity immunotherapy. Adv. Mater. 35, e2207686 (2023).","journal-title":"Adv. Mater."},{"key":"2810_CR164","doi-asserted-by":"publisher","first-page":"706","DOI":"10.2337\/db21-0209","volume":"71","author":"I Kavazovi\u0107","year":"2022","unstructured":"Kavazovi\u0107, I. et al. Hyperglycemia and not hyperinsulinemia mediates diabetes-induced memory CD8 T-cell dysfunction. Diabetes 71, 706\u2013721 (2022).","journal-title":"Diabetes"},{"key":"2810_CR165","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1038\/s41590-018-0251-7","volume":"19","author":"X Michelet","year":"2018","unstructured":"Michelet, X. et al. Metabolic reprogramming of natural killer cells in obesity limits antitumor responses. Nat. Immunol. 19, 1330\u20131340 (2018).","journal-title":"Nat. Immunol."},{"key":"2810_CR166","doi-asserted-by":"publisher","first-page":"e000725","DOI":"10.1136\/jitc-2020-000725","volume":"8","author":"SK Boi","year":"2020","unstructured":"Boi, S. K. et al. Obesity diminishes response to PD-1-based immunotherapies in renal cancer. J. Immunother. Cancer 8, e000725 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"2810_CR167","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1073\/pnas.1812266115","volume":"116","author":"I Kaplanov","year":"2019","unstructured":"Kaplanov, I. et al. Blocking IL-1\u03b2 reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation. Proc. Natl. Acad. Sci. USA 116, 1361\u20131369 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2810_CR168","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1158\/2326-6066.CIR-18-0578","volume":"7","author":"CS Tannenbaum","year":"2019","unstructured":"Tannenbaum, C. S. et al. Mediators of inflammation-driven expansion, trafficking, and function of tumor-infiltrating MDSCs. Cancer Immunol. Res. 7, 1687\u20131699 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"2810_CR169","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1012016","volume":"13","author":"LV Vick","year":"2022","unstructured":"Vick, L. V. et al. Aging augments obesity-induced thymic involution and peripheral T cell exhaustion altering the \u201cobesity paradox\u201d. Front. Immunol. 13, 1012016 (2022).","journal-title":"Front. Immunol."},{"key":"2810_CR170","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3389\/fimmu.2020.00827","volume":"11","author":"B Diao","year":"2020","unstructured":"Diao, B. et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 11, 827 (2020).","journal-title":"Front Immunol."},{"key":"2810_CR171","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","volume":"37","author":"LM McLane","year":"2019","unstructured":"McLane, L. M., Abdel-Hakeem, M. S. & Wherry, E. J. CD8 T cell exhaustion during chronic viral infection and cancer. Annu. Rev. Immunol. 37, 457\u2013495 (2019).","journal-title":"Annu. Rev. Immunol."},{"key":"2810_CR172","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.2169\/internalmedicine.3726-19","volume":"59","author":"R Fukuda","year":"2020","unstructured":"Fukuda, R., Sugawara, S. & Kondo, Y. Immune checkpoint inhibitor can reduce HCV-RNA without liver damage. Intern. Med. 59, 2245\u20132248 (2020).","journal-title":"Intern. Med."},{"key":"2810_CR173","doi-asserted-by":"publisher","first-page":"eaai7616","DOI":"10.1126\/sciimmunol.aai7616","volume":"2","author":"M Ghazarian","year":"2017","unstructured":"Ghazarian, M. et al. Type I interferon responses drive intrahepatic T cells to promote metabolic syndrome. Sci. Immunol. 2, eaai7616 (2017).","journal-title":"Sci. Immunol."},{"key":"2810_CR174","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42432-x","volume":"14","author":"M Almond","year":"2023","unstructured":"Almond, M. et al. Obesity dysregulates the pulmonary antiviral immune response. Nat. Commun. 14, 6607 (2023).","journal-title":"Nat. Commun."},{"key":"2810_CR175","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1172\/JCI31986","volume":"117","author":"T Nomiyama","year":"2007","unstructured":"Nomiyama, T. et al. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J. Clin. Investig. 117, 2877\u20132888 (2007).","journal-title":"J. Clin. Investig."},{"key":"2810_CR176","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.cmet.2009.08.003","volume":"10","author":"M Tabata","year":"2009","unstructured":"Tabata, M. et al. Angiopoietin-like protein 2 promotes chronic adipose tissue inflammation and obesity-related systemic insulin resistance. Cell Metab. 10, 178\u2013188 (2009).","journal-title":"Cell Metab."},{"key":"2810_CR177","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.bbrc.2013.07.034","volume":"438","author":"M Fujii","year":"2013","unstructured":"Fujii, M. et al. CTLA-4Ig immunotherapy of obesity-induced insulin resistance by manipulation of macrophage polarization in adipose tissues. Biochem. Biophys. Res Commun. 438, 103\u2013109 (2013).","journal-title":"Biochem. Biophys. Res Commun."},{"key":"2810_CR178","doi-asserted-by":"publisher","first-page":"e20221391","DOI":"10.1084\/jem.20221391","volume":"220","author":"X Xu","year":"2023","unstructured":"Xu, X. et al. CTLA4 depletes T cell endogenous and trogocytosed B7 ligands via cis-endocytosis. J. Exp. Med. 220, e20221391 (2023).","journal-title":"J. Exp. Med."},{"key":"2810_CR179","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04532-6","volume":"21","author":"S Ji","year":"2023","unstructured":"Ji, S. et al. Cancer stem cell-derived CHI3L1 activates the MAF\/CTLA4 signaling pathway to promote immune escape in triple-negative breast cancer. J. Transl. Med. 21, 721 (2023).","journal-title":"J. Transl. Med."},{"key":"2810_CR180","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/ijo.2015.26","volume":"39","author":"M Poggi","year":"2015","unstructured":"Poggi, M. et al. CD28 deletion improves obesity-induced liver steatosis but increases adiposity in mice. Int. J. Obes. (Lond.) 39, 977\u2013985 (2015).","journal-title":"Int. J. Obes. (Lond.)"},{"key":"2810_CR181","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s40425-019-0512-5","volume":"7","author":"GS Naik","year":"2019","unstructured":"Naik, G. S. et al. Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition. J. Immunother. Cancer 7, 89 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"2810_CR182","unstructured":"Hahn, A. W. et al. in Clinical Cancer Research Vol. 29, 154\u2013164 (\u00a92022 American Association for Cancer Research, 2023)."},{"key":"2810_CR183","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/bjc.2016.431","volume":"116","author":"LE Daly","year":"2017","unstructured":"Daly, L. E. et al. The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. Br. J. Cancer 116, 310\u2013317 (2017).","journal-title":"Br. J. Cancer"},{"key":"2810_CR184","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1001\/jamaoncol.2021.0019","volume":"7","author":"AA Lalani","year":"2021","unstructured":"Lalani, A. A. et al. Assessment of immune checkpoint inhibitors and genomic alterations by body mass index in advanced renal cell carcinoma. JAMA Oncol. 7, 773\u2013775 (2021).","journal-title":"JAMA Oncol."},{"key":"2810_CR185","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1016\/j.clgc.2023.03.006","volume":"21","author":"M Santoni","year":"2023","unstructured":"Santoni, M. et al. Clinico-pathological features influencing the prognostic role of body mass index in patients with advanced renal cell carcinoma treated by immuno-oncology combinations (ARON-1). Clin. Genitourin. Cancer 21, e309\u2013e319.e301 (2023).","journal-title":"Clin. Genitourin. Cancer"},{"key":"2810_CR186","doi-asserted-by":"publisher","first-page":"5180","DOI":"10.1158\/1078-0432.CCR-22-1389","volume":"28","author":"Y Ged","year":"2022","unstructured":"Ged, Y. et al. Associations between pretreatment body composition features and clinical outcomes among patients with metastatic clear cell renal cell carcinoma treated with immune checkpoint blockade. Clin. Cancer Res. 28, 5180\u20135189 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2810_CR187","doi-asserted-by":"publisher","first-page":"e220448","DOI":"10.1001\/jamanetworkopen.2022.0448","volume":"5","author":"SK Yoo","year":"2022","unstructured":"Yoo, S. K. et al. JAMA Netw. Open 5, e220448 (2022).","journal-title":"JAMA Netw. Open"},{"key":"2810_CR188","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","volume":"39","author":"DL Jardim","year":"2021","unstructured":"Jardim, D. L., Goodman, A., de Melo Gagliato, D. & Kurzrock, R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell 39, 154\u2013173 (2021).","journal-title":"Cancer Cell"},{"key":"2810_CR189","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers, Z. R. et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 9, 34 (2017).","journal-title":"Genome Med."},{"key":"2810_CR190","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.11306","volume":"9","author":"M Hu","year":"2021","unstructured":"Hu, M. et al. The regulation of immune checkpoints by the hypoxic tumor microenvironment. PeerJ. 9, e11306 (2021).","journal-title":"PeerJ."},{"key":"2810_CR191","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1189\/jlb.3A0115-009R","volume":"99","author":"DL Morris","year":"2016","unstructured":"Morris, D. L. et al. CD40 promotes MHC class II expression on adipose tissue macrophages and regulates adipose tissue CD4+ T cells with obesity. J. Leukoc. Biol. 99, 1107\u20131119 (2016).","journal-title":"J. Leukoc. Biol."},{"key":"2810_CR192","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.mce.2011.04.004","volume":"339","author":"M Keuper","year":"2011","unstructured":"Keuper, M. et al. An inflammatory micro-environment promotes human adipocyte apoptosis. Mol. Cell. Endocrinol. 339, 105\u2013113 (2011).","journal-title":"Mol. Cell. Endocrinol."},{"key":"2810_CR193","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/ije\/dyu045","volume":"43","author":"MC Harps\u00f8e","year":"2014","unstructured":"Harps\u00f8e, M. C. et al. Body mass index and risk of autoimmune diseases: a study within the Danish National Birth Cohort. Int. J. Epidemiol. 43, 843\u2013855 (2014).","journal-title":"Int. J. Epidemiol."},{"key":"2810_CR194","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.semcancer.2019.06.012","volume":"64","author":"S Khan","year":"2020","unstructured":"Khan, S. & Gerber, D. E. Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: a review. Semin. Cancer Biol. 64, 93\u2013101 (2020).","journal-title":"Semin. Cancer Biol."},{"key":"2810_CR195","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s40425-019-0699-5","volume":"7","author":"D Donnelly","year":"2019","unstructured":"Donnelly, D. et al. The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients. J. Immunother. Cancer 7, 222 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"2810_CR196","doi-asserted-by":"publisher","first-page":"7630","DOI":"10.3390\/ijms24087630","volume":"24","author":"MV Deligiorgi","year":"2023","unstructured":"Deligiorgi, M. V. & Trafalis, D. T. A concerted vision to advance the knowledge of diabetes mellitus related to immune checkpoint inhibitors. Int. J. Mol. Sci. 24, 7630 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2810_CR197","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e37278","volume":"10","author":"ML Zhao","year":"2024","unstructured":"Zhao, M. L. et al. Inhibition of CTLA-4 accelerates atherosclerosis in hyperlipidemic mice by modulating the Th1\/Th2 balance via the NF-\u03baB signaling pathway. Heliyon 10, e37278 (2024).","journal-title":"Heliyon"},{"key":"2810_CR198","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ejca.2023.01.030","volume":"184","author":"P Trinkner","year":"2023","unstructured":"Trinkner, P. et al. Survival and immunotoxicities in association with sex-specific body composition patterns of cancer patients undergoing immune-checkpoint inhibitor therapy\u2014a systematic review and meta-analysis. Eur. J. Cancer 184, 151\u2013171 (2023).","journal-title":"Eur. J. Cancer"},{"key":"2810_CR199","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s10637-017-0464-x","volume":"35","author":"V Heidelberger","year":"2017","unstructured":"Heidelberger, V. et al. Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients. Investig. N. Drugs 35, 436\u2013441 (2017).","journal-title":"Investig. N. Drugs"},{"key":"2810_CR200","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00262-020-02663-z","volume":"70","author":"Y Guzman-Prado","year":"2021","unstructured":"Guzman-Prado, Y., Ben Shimol, J. & Samson, O. Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: a systematic review and meta-analysis. Cancer Immunol. Immunother. 70, 89\u2013100 (2021).","journal-title":"Cancer Immunol. Immunother."},{"key":"2810_CR201","doi-asserted-by":"publisher","first-page":"ltac015","DOI":"10.1093\/immadv\/ltac015","volume":"2","author":"G Pasquarelli-do-Nascimento","year":"2022","unstructured":"Pasquarelli-do-Nascimento, G., Machado, S. A., de Carvalho, J. M. A. & Magalh\u00e3es, K. G. Obesity and adipose tissue impact on T-cell response and cancer immune checkpoint blockade therapy. Immunother. Adv. 2, ltac015 (2022).","journal-title":"Immunother. Adv."},{"key":"2810_CR202","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1172\/JCI127201","volume":"129","author":"Y Cao","year":"2019","unstructured":"Cao, Y. Adipocyte and lipid metabolism in cancer drug resistance. J. Clin. Investig. 129, 3006\u20133017 (2019).","journal-title":"J. Clin. Investig."},{"key":"2810_CR203","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s42255-019-0032-0","volume":"1","author":"AM Intlekofer","year":"2019","unstructured":"Intlekofer, A. M. & Finley, L. W. S. Metabolic signatures of cancer cells and stem cells. Nat. Metab. 1, 177\u2013188 (2019).","journal-title":"Nat. Metab."},{"key":"2810_CR204","doi-asserted-by":"publisher","first-page":"eaav2501","DOI":"10.1126\/science.aav2501","volume":"364","author":"D Merrick","year":"2019","unstructured":"Merrick, D. et al. Identification of a mesenchymal progenitor cell hierarchy in adipose tissue. Science 364, eaav2501 (2019).","journal-title":"Science"},{"key":"2810_CR205","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abm7012","volume":"8","author":"E Picarda","year":"2022","unstructured":"Picarda, E. et al. The immune checkpoint B7-H3 (CD276) regulates adipocyte progenitor metabolism and obesity development. Sci. Adv. 8, eabm7012 (2022).","journal-title":"Sci. Adv."},{"key":"2810_CR206","doi-asserted-by":"publisher","first-page":"e139793","DOI":"10.1172\/jci.insight.139793","volume":"6","author":"CE Porsche","year":"2021","unstructured":"Porsche, C. E. et al. Obesity results in adipose tissue T cell exhaustion. JCI Insight 6, e139793 (2021).","journal-title":"JCI Insight"},{"key":"2810_CR207","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1111\/cas.15311","volume":"113","author":"Y Xu","year":"2022","unstructured":"Xu, Y. et al. Dahuang Fuzi Baijiang decoction restricts progenitor to terminally exhausted T cell differentiation in colorectal cancer. Cancer Sci. 113, 1739\u20131751 (2022).","journal-title":"Cancer Sci."},{"key":"2810_CR208","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109212","volume":"35","author":"MD Mana","year":"2021","unstructured":"Mana, M. D. et al. High-fat diet-activated fatty acid oxidation mediates intestinal stemness and tumorigenicity. Cell Rep. 35, 109212 (2021).","journal-title":"Cell Rep."},{"key":"2810_CR209","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1152\/physrev.00015.2009","volume":"90","author":"GD Lopaschuk","year":"2010","unstructured":"Lopaschuk, G. D. et al. Myocardial fatty acid metabolism in health and disease. Physiol. Rev. 90, 207\u2013258 (2010).","journal-title":"Physiol. Rev."},{"key":"2810_CR210","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1267578","volume":"14","author":"M Rezaei","year":"2023","unstructured":"Rezaei, M. et al. TIM-3\/Gal-9 interaction affects glucose and lipid metabolism in acute myeloid leukemia cell lines. Front. Immunol. 14, 1267578 (2023).","journal-title":"Front. Immunol."},{"key":"2810_CR211","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3389\/fimmu.2020.00148","volume":"11","author":"HC Tao","year":"2020","unstructured":"Tao, H. C. et al. CD47 deficiency in mice exacerbates chronic fatty diet-induced steatohepatitis through its role in regulating hepatic inflammation and lipid metabolism. Front. Immunol. 11, 148 (2020).","journal-title":"Front. Immunol."},{"key":"2810_CR212","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29137-3","volume":"13","author":"N Jiang","year":"2022","unstructured":"Jiang, N. et al. Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion. Nat. Commun. 13, 1511 (2022).","journal-title":"Nat. Commun."},{"key":"2810_CR213","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ccell.2020.04.017","volume":"38","author":"R Su","year":"2020","unstructured":"Su, R. et al. Targeting FTO suppresses cancer stem cell maintenance and immune evasion. Cancer Cell 38, 79\u201396.e11 (2020).","journal-title":"Cancer Cell"},{"key":"2810_CR214","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrendo.2013.227","volume":"10","author":"RJ Loos","year":"2014","unstructured":"Loos, R. J. & Yeo, G. S. The bigger picture of FTO: the first GWAS-identified obesity gene. Nat. Rev. Endocrinol. 10, 51\u201361 (2014).","journal-title":"Nat. Rev. Endocrinol."},{"key":"2810_CR215","first-page":"1355","volume":"58","author":"J Mayfield","year":"1998","unstructured":"Mayfield, J. Diagnosis and classification of diabetes mellitus: new criteria. Am. Fam. Physician 58, 1355\u20131362 (1998). 1369\u20131370.","journal-title":"Am. Fam. Physician"},{"key":"2810_CR216","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.2337\/dc23-S002","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed, N. A. et al. 2. Classification and diagnosis of diabetes: standards of care in diabetes\u20142023. Diab. Care 46, S19\u2013s40 (2023).","journal-title":"Diab. Care"},{"key":"2810_CR217","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1146\/annurev.immunol.23.021704.115643","volume":"23","author":"MS Anderson","year":"2005","unstructured":"Anderson, M. S. & Bluestone, J. A. The NOD mouse: a model of immune dysregulation. Annu. Rev. Immunol. 23, 447\u2013485 (2005).","journal-title":"Annu. Rev. Immunol."},{"key":"2810_CR218","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/ncpendmet0082","volume":"2","author":"S Cernea","year":"2006","unstructured":"Cernea, S. & Herold, K. C. Drug insight: New immunomodulatory therapies in type 1 diabetes. Nat. Clin. Pract. Endocrinol. Metab. 2, 89\u201398 (2006).","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"key":"2810_CR219","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nrendo.2013.131","volume":"9","author":"LA Velloso","year":"2013","unstructured":"Velloso, L. A., Eizirik, D. L. & Cnop, M. Type 2 diabetes mellitus\u2014an autoimmune disease? Nat. Rev. Endocrinol. 9, 750\u2013755 (2013).","journal-title":"Nat. Rev. Endocrinol."},{"key":"2810_CR220","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.humimm.2014.02.007","volume":"75","author":"C Zhang","year":"2014","unstructured":"Zhang, C. et al. The alteration of Th1\/Th2\/Th17\/Treg paradigm in patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Hum. Immunol. 75, 289\u2013296 (2014).","journal-title":"Hum. Immunol."},{"key":"2810_CR221","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.cmet.2018.12.003","volume":"29","author":"W Ying","year":"2019","unstructured":"Ying, W. et al. Expansion of islet-resident macrophages leads to inflammation affecting \u03b2 cell proliferation and function in obesity. Cell Metab. 29, 457\u2013474.e455 (2019).","journal-title":"Cell Metab."},{"key":"2810_CR222","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1159\/000356747","volume":"60","author":"BK Itariu","year":"2014","unstructured":"Itariu, B. K. & Stulnig, T. M. Autoimmune aspects of type 2 diabetes mellitus\u2014a mini-review. Gerontology 60, 189\u2013196 (2014).","journal-title":"Gerontology"},{"key":"2810_CR223","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.jmb.2019.09.016","volume":"432","author":"M Lytrivi","year":"2020","unstructured":"Lytrivi, M., Castell, A. L., Poitout, V. & Cnop, M. Recent insights into mechanisms of \u03b2-cell lipo- and glucolipotoxicity in type 2 diabetes. J. Mol. Biol. 432, 1514\u20131534 (2020).","journal-title":"J. Mol. Biol."},{"key":"2810_CR224","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12929-016-0307-7","volume":"24","author":"HC Chuang","year":"2017","unstructured":"Chuang, H. C. & Tan, T. H. MAP4K4 and IL-6(+) Th17 cells play important roles in non-obese type 2 diabetes. J. Biomed. Sci. 24, 4 (2017).","journal-title":"J. Biomed. Sci."},{"key":"2810_CR225","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.cmet.2018.09.008","volume":"29","author":"E Zhang","year":"2019","unstructured":"Zhang, E. et al. Preserving Insulin Secretion In Diabetes By Inhibiting VDAC1 overexpression and surface translocation in \u03b2 cells. Cell Metab. 29, 64\u201377.e66 (2019).","journal-title":"Cell Metab."},{"key":"2810_CR226","doi-asserted-by":"publisher","first-page":"2518797","DOI":"10.1080\/23288604.2025.2518797","volume":"11","author":"B McPake","year":"2025","unstructured":"McPake, B. Overweight, obesity and diabetes: global trends and a better future? Health Syst. Reform 11, 2518797 (2025).","journal-title":"Health Syst. Reform"},{"key":"2810_CR227","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0165-2478(02)00142-6","volume":"84","author":"M Ishida","year":"2002","unstructured":"Ishida, M. et al. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol. Lett. 84, 57\u201362 (2002).","journal-title":"Immunol. Lett."},{"key":"2810_CR228","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/cei.12603","volume":"180","author":"R Fujisawa","year":"2015","unstructured":"Fujisawa, R. et al. Low programmed cell death-1 (PD-1) expression in peripheral CD4(+) T cells in Japanese patients with autoimmune type 1 diabetes. Clin. Exp. Immunol. 180, 452\u2013457 (2015).","journal-title":"Clin. Exp. Immunol."},{"key":"2810_CR229","first-page":"e1164","volume":"3","author":"T Martinov","year":"2016","unstructured":"Martinov, T., Spanier, J. A., Pauken, K. E. & Fife, B. T. PD-1 pathway-mediated regulation of islet-specific CD4(+) T cell subsets in autoimmune diabetes. Immunoendocrinology (Houston) 3, e1164 (2016).","journal-title":"Immunoendocrinology (Houston)"},{"key":"2810_CR230","doi-asserted-by":"publisher","first-page":"22584","DOI":"10.3390\/ijms160922584","volume":"16","author":"V Perri","year":"2015","unstructured":"Perri, V. et al. Expression of PD-1 molecule on regulatory T lymphocytes in patients with insulin-dependent diabetes mellitus. Int. J. Mol. Sci. 16, 22584\u201322605 (2015).","journal-title":"Int. J. Mol. Sci."},{"key":"2810_CR231","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1007\/s00125-019-4936-8","volume":"62","author":"I Ekman","year":"2019","unstructured":"Ekman, I. et al. Circulating CXCR5(-)PD-1(hi) peripheral T helper cells are associated with progression to type 1 diabetes. Diabetologia 62, 1681\u20131688 (2019).","journal-title":"Diabetologia"},{"key":"2810_CR232","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1146\/annurev-immunol-042617-053214","volume":"37","author":"D Masopust","year":"2019","unstructured":"Masopust, D. & Soerens, A. G. Tissue-resident T cells and other resident leukocytes. Annu. Rev. Immunol. 37, 521\u2013546 (2019).","journal-title":"Annu. Rev. Immunol."},{"key":"2810_CR233","doi-asserted-by":"publisher","first-page":"3916","DOI":"10.1016\/j.celrep.2019.11.056","volume":"29","author":"SP Weisberg","year":"2019","unstructured":"Weisberg, S. P. et al. Tissue-Resident Memory T Cells Mediate Immune Homeostasis in the Human Pancreas through the PD-1\/PD-L1 Pathway. Cell Rep. 29, 3916\u20133932.e3915 (2019).","journal-title":"Cell Rep."},{"key":"2810_CR234","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s00125-024-06313-2","volume":"68","author":"C Rao","year":"2025","unstructured":"Rao, C. et al. Beta cell extracellular vesicle PD-L1 as a novel regulator of CD8(+) T cell activity and biomarker during the evolution of type 1 diabetes. Diabetologia 68, 382\u2013396 (2025).","journal-title":"Diabetologia"},{"key":"2810_CR235","doi-asserted-by":"publisher","first-page":"11823","DOI":"10.1073\/pnas.0505497102","volume":"102","author":"J Wang","year":"2005","unstructured":"Wang, J. et al. Establishment of NOD-Pdcd1\u2212\/\u2212 mice as an efficient animal model of type I diabetes. Proc. Natl. Acad. Sci. USA 102, 11823\u201311828 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2810_CR236","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.4049\/jimmunol.1402262","volume":"194","author":"KE Pauken","year":"2015","unstructured":"Pauken, K. E. et al. Cutting edge: identification of autoreactive CD4+ and CD8+ T cell subsets resistant to PD-1 pathway blockade. J. Immunol. 194, 3551\u20133555 (2015).","journal-title":"J. Immunol."},{"key":"2810_CR237","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.clim.2007.05.013","volume":"125","author":"I Guleria","year":"2007","unstructured":"Guleria, I. et al. Mechanisms of PDL1-mediated regulation of autoimmune diabetes. Clin. Immunol. 125, 16\u201325 (2007).","journal-title":"Clin. Immunol."},{"key":"2810_CR238","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.2337\/db12-1475","volume":"62","author":"KE Pauken","year":"2013","unstructured":"Pauken, K. E., Jenkins, M. K., Azuma, M. & Fife, B. T. PD-1, but not PD-L1, expressed by islet-reactive CD4+ T cells suppresses infiltration of the pancreas during type 1 diabetes. Diabetes 62, 2859\u20132869 (2013).","journal-title":"Diabetes"},{"key":"2810_CR239","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1084\/jem.20061577","volume":"203","author":"BT Fife","year":"2006","unstructured":"Fife, B. T. et al. Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J. Exp. Med. 203, 2737\u20132747 (2006).","journal-title":"J. Exp. Med."},{"key":"2810_CR240","doi-asserted-by":"publisher","first-page":"511","DOI":"10.2337\/db22-0557","volume":"72","author":"S Kawata","year":"2023","unstructured":"Kawata, S. et al. Inflammatory cell infiltration into islets without PD-L1 expression is associated with the development of immune checkpoint inhibitor-related type 1 diabetes in genetically susceptible patients. Diabetes 72, 511\u2013519 (2023).","journal-title":"Diabetes"},{"key":"2810_CR241","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.16","volume":"3","author":"A Katsarou","year":"2017","unstructured":"Katsarou, A. et al. Type 1 diabetes mellitus. Nat. Rev. Dis. Prim. 3, 17016 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2810_CR242","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.2337\/db07-1260","volume":"57","author":"CJ Wang","year":"2008","unstructured":"Wang, C. J. et al. Protective role of programmed death 1 ligand 1 (PD-L1) in nonobese diabetic mice: the paradox in transgenic models. Diabetes 57, 1861\u20131869 (2008).","journal-title":"Diabetes"},{"key":"2810_CR243","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.it.2016.11.004","volume":"38","author":"LK Mackay","year":"2017","unstructured":"Mackay, L. K. & Kallies, A. Transcriptional regulation of tissue-resident lymphocytes. Trends Immunol. 38, 94\u2013103 (2017).","journal-title":"Trends Immunol."},{"key":"2810_CR244","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1084\/jem.20051776","volume":"203","author":"ME Keir","year":"2006","unstructured":"Keir, M. E. et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. 203, 883\u2013895 (2006).","journal-title":"J. Exp. Med."},{"key":"2810_CR245","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.4049\/jimmunol.179.8.5064","volume":"179","author":"ME Keir","year":"2007","unstructured":"Keir, M. E., Freeman, G. J. & Sharpe, A. H. PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues. J. Immunol. 179, 5064\u20135070 (2007).","journal-title":"J. Immunol."},{"key":"2810_CR246","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ebiom.2018.09.040","volume":"36","author":"ML Colli","year":"2018","unstructured":"Colli, M. L. et al. PDL1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons-\u03b1 and-\u03b3 via IRF1 induction. EBioMedicine. 36, 367\u2013375 (2018).","journal-title":"EBioMedicine."},{"key":"2810_CR247","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/ni.1790","volume":"10","author":"BT Fife","year":"2009","unstructured":"Fife, B. T. et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat. Immunol. 10, 1185\u20131192 (2009).","journal-title":"Nat. Immunol."},{"key":"2810_CR248","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/jdi.12531","volume":"7","author":"M Okamoto","year":"2016","unstructured":"Okamoto, M. et al. Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy. J. Diab. Investig. 7, 915\u2013918 (2016).","journal-title":"J. Diab. Investig."},{"key":"2810_CR249","doi-asserted-by":"publisher","first-page":"885001","DOI":"10.3389\/fpubh.2022.885001","volume":"10","author":"C Lin","year":"2022","unstructured":"Lin, C. et al. PD-1 inhibitor-associated type 1 diabetes: a case report and systematic review. Front. Public Health 10, 885001 (2022).","journal-title":"Front. Public Health"},{"key":"2810_CR250","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.2337\/dbi18-0002","volume":"67","author":"AM Stamatouli","year":"2018","unstructured":"Stamatouli, A. M. et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes 67, 1471\u20131480 (2018).","journal-title":"Diabetes"},{"key":"2810_CR251","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.2337\/db09-1135","volume":"59","author":"T Rajasalu","year":"2010","unstructured":"Rajasalu, T. et al. Deficiency in B7-H1 (PD-L1)\/PD-1 coinhibition triggers pancreatic beta-cell destruction by insulin-specific, murine CD8 T-cells. Diabetes 59, 1966\u20131973 (2010).","journal-title":"Diabetes"},{"key":"2810_CR252","doi-asserted-by":"publisher","first-page":"813","DOI":"10.2337\/diacare.27.3.813","volume":"27","author":"JC Pickup","year":"2004","unstructured":"Pickup, J. C. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diab. Care 27, 813\u2013823 (2004).","journal-title":"Diab. Care"},{"key":"2810_CR253","volume":"2018","author":"T Zhou","year":"2018","unstructured":"Zhou, T. et al. Role of adaptive and innate immunity in type 2 diabetes mellitus. J. Diab. Res. 2018, 7457269 (2018).","journal-title":"J. Diab. Res."},{"key":"2810_CR254","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1750-3639.2000.tb00239.x","volume":"10","author":"U Felderhoff-Mueser","year":"2000","unstructured":"Felderhoff-Mueser, U. et al. Fas\/CD95\/APO-1 can function as a death receptor for neuronal cells in vitro and in vivo and is upregulated following cerebral hypoxic-ischemic injury to the developing rat brain. Brain Pathol. 10, 17\u201329 (2000).","journal-title":"Brain Pathol."},{"key":"2810_CR255","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/ni.2762","volume":"14","author":"T Okazaki","year":"2013","unstructured":"Okazaki, T. et al. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat. Immunol. 14, 1212\u20131218 (2013).","journal-title":"Nat. Immunol."},{"key":"2810_CR256","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.metabol.2012.12.005","volume":"62","author":"B Shi","year":"2013","unstructured":"Shi, B. et al. Increased PD-1 on CD4(+)CD28(-) T cell and soluble PD-1 ligand-1 in patients with T2DM: association with atherosclerotic macrovascular diseases. Metabolism 62, 778\u2013785 (2013).","journal-title":"Metabolism"},{"key":"2810_CR257","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00592-023-02055-6","volume":"60","author":"Z Su","year":"2023","unstructured":"Su, Z. et al. Heterogeneity of circulating CXCR5-PD-1(hi)Tph cells in patients of type 2 and type 1 diabetes in Chinese population. Acta Diabetol. 60, 767\u2013776 (2023).","journal-title":"Acta Diabetol."},{"key":"2810_CR258","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.yexmp.2012.11.004","volume":"94","author":"B Baban","year":"2013","unstructured":"Baban, B., Liu, J. Y. & Mozaffari, M. S. Endoplasmic reticulum stress response and inflammatory cytokines in type 2 diabetic nephropathy: role of indoleamine 2,3-dioxygenase and programmed death-1. Exp. Mol. Pathol. 94, 343\u2013351 (2013).","journal-title":"Exp. Mol. Pathol."},{"key":"2810_CR259","volume":"2019","author":"P Sun","year":"2019","unstructured":"Sun, P. et al. Unlike PD-L1, PD-1 is downregulated on partial immune cells in type 2 diabetes. J. Diab. Res. 2019, 5035261 (2019).","journal-title":"J. Diab. Res."},{"key":"2810_CR260","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ccell.2022.05.004","volume":"40","author":"K Kersten","year":"2022","unstructured":"Kersten, K. et al. Spatiotemporal co-dependency between macrophages and exhausted CD8(+) T cells in cancer. Cancer Cell 40, 624\u2013638.e629 (2022).","journal-title":"Cancer Cell"},{"key":"2810_CR261","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26940-2","volume":"12","author":"AH Lee","year":"2021","unstructured":"Lee, A. H. et al. Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Nat. Commun. 12, 6938 (2021).","journal-title":"Nat. Commun."},{"key":"2810_CR262","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/nature05894","volume":"447","author":"JI Odegaard","year":"2007","unstructured":"Odegaard, J. I. et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447, 1116\u20131120 (2007).","journal-title":"Nature"},{"key":"2810_CR263","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/s13311-013-0254-x","volume":"11","author":"A Yao","year":"2014","unstructured":"Yao, A. et al. Programmed death 1 deficiency induces the polarization of macrophages\/microglia to the M1 phenotype after spinal cord injury in mice. Neurotherapeutics 11, 636\u2013650 (2014).","journal-title":"Neurotherapeutics"},{"key":"2810_CR264","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1677\/jme.0.0240297","volume":"24","author":"S Bonner-Weir","year":"2000","unstructured":"Bonner-Weir, S. Islet growth and development in the adult. J. Mol. Endocrinol. 24, 297\u2013302 (2000).","journal-title":"J. Mol. Endocrinol."},{"key":"2810_CR265","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41574-019-0286-3","volume":"16","author":"W Ying","year":"2020","unstructured":"Ying, W., Fu, W., Lee, Y. S. & Olefsky, J. M. The role of macrophages in obesity-associated islet inflammation and \u03b2-cell abnormalities. Nat. Rev. Endocrinol. 16, 81\u201390 (2020).","journal-title":"Nat. Rev. Endocrinol."},{"key":"2810_CR266","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s11010-022-04587-x","volume":"478","author":"K Ramasubbu","year":"2023","unstructured":"Ramasubbu, K. & Devi Rajeswari, V. Impairment of insulin signaling pathway PI3K\/Akt\/mTOR and insulin resistance induced AGEs on diabetes mellitus and neurodegenerative diseases: a perspective review. Mol. Cell. Biochem. 478, 1307\u20131324 (2023).","journal-title":"Mol. Cell. Biochem."},{"key":"2810_CR267","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.cmet.2018.08.003","volume":"28","author":"S Tsai","year":"2018","unstructured":"Tsai, S. et al. Insulin receptor-mediated stimulation boosts T cell immunity during inflammation and infection. Cell Metab. 28, 922\u2013934.e924 (2018).","journal-title":"Cell Metab."},{"key":"2810_CR268","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/s41590-018-0224-x","volume":"19","author":"LA Dempsey","year":"2018","unstructured":"Dempsey, L. A. Anti-tumor role of metformin. Nat. Immunol. 19, 1039 (2018).","journal-title":"Nat. Immunol."},{"key":"2810_CR269","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.tips.2018.07.006","volume":"39","author":"A Vancura","year":"2018","unstructured":"Vancura, A. et al. Metformin as an anticancer agent. Trends Pharm. Sci. 39, 867\u2013878 (2018).","journal-title":"Trends Pharm. Sci."},{"key":"2810_CR270","doi-asserted-by":"publisher","first-page":"Lmt11","DOI":"10.2217\/lmt-2018-0016","volume":"8","author":"MZ Afzal","year":"2019","unstructured":"Afzal, M. Z., Dragnev, K., Sarwar, T. & Shirai, K. Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors. Lung Cancer Manag. 8, Lmt11 (2019).","journal-title":"Lung Cancer Manag."},{"key":"2810_CR271","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s40425-018-0375-1","volume":"6","author":"MZ Afzal","year":"2018","unstructured":"Afzal, M. Z., Mercado, R. R. & Shirai, K. Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1\/anti-CTLA-4) in metastatic malignant melanoma. J. Immunother. Cancer 6, 64 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"2810_CR272","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.molcel.2018.07.030","volume":"71","author":"JH Cha","year":"2018","unstructured":"Cha, J. H. et al. Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1. Mol. Cell 71, 606\u2013620.e607 (2018).","journal-title":"Mol. Cell"},{"key":"2810_CR273","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.172541","volume":"859","author":"J Xue","year":"2019","unstructured":"Xue, J. et al. Metformin suppresses cancer cell growth in endometrial carcinoma by inhibiting PD-L1. Eur. J. Pharm. 859, 172541 (2019).","journal-title":"Eur. J. Pharm."},{"key":"2810_CR274","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3343\/alm.2023.0443","volume":"44","author":"SH Park","year":"2024","unstructured":"Park, S. H. et al. Metformin suppresses both PD-L1 expression in cancer cells and cancer-induced PD-1 expression in immune cells to promote antitumor immunity. Ann. Lab. Med. 44, 426\u2013436 (2024).","journal-title":"Ann. Lab. Med."},{"key":"2810_CR275","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00262-020-02703-8","volume":"70","author":"Y Kim","year":"2021","unstructured":"Kim, Y. et al. Overcoming acquired resistance to PD-1 inhibitor with the addition of metformin in small cell lung cancer (SCLC). Cancer Immunol. Immunother. 70, 961\u2013965 (2021).","journal-title":"Cancer Immunol. Immunother."},{"key":"2810_CR276","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.cmet.2020.01.015","volume":"31","author":"A Gonz\u00e1lez","year":"2020","unstructured":"Gonz\u00e1lez, A., Hall, M. N., Lin, S. C. & Hardie, D. G. AMPK and TOR: the Yin and Yang of cellular nutrient sensing and growth control. Cell Metab. 31, 472\u2013492 (2020).","journal-title":"Cell Metab."},{"key":"2810_CR277","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1158\/2326-6066.CIR-16-0103","volume":"5","author":"NE Scharping","year":"2017","unstructured":"Scharping, N. E. et al. Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia. Cancer Immunol. Res. 5, 9\u201316 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"2810_CR278","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20723-x","volume":"12","author":"Z Wei","year":"2021","unstructured":"Wei, Z. et al. Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles. Nat. Commun. 12, 440 (2021).","journal-title":"Nat. Commun."},{"key":"2810_CR279","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41591-021-01584-3","volume":"28","author":"CT Ruff","year":"2022","unstructured":"Ruff, C. T. et al. Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial. Nat. Med. 28, 89\u201395 (2022).","journal-title":"Nat. Med."},{"key":"2810_CR280","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.semcancer.2021.07.011","volume":"79","author":"L Cristinziano","year":"2022","unstructured":"Cristinziano, L. et al. Neutrophil extracellular traps in cancer. Semin. Cancer Biol. 79, 91\u2013104 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"2810_CR281","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.bbrc.2022.06.052","volume":"619","author":"D Chen","year":"2022","unstructured":"Chen, D. et al. Exenatide enhanced the antitumor efficacy on PD-1 blockade by the attenuation of neutrophil extracellular traps. Biochem. Biophys. Res. Commun. 619, 97\u2013103 (2022).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2810_CR282","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ejphar.2016.10.016","volume":"791","author":"F Zhou","year":"2016","unstructured":"Zhou, F. et al. Liraglutide attenuates lipopolysaccharide-induced acute lung injury in mice. Eur. J. Pharm. 791, 735\u2013740 (2016).","journal-title":"Eur. J. Pharm."},{"key":"2810_CR283","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1002\/2211-5463.13499","volume":"14","author":"D Chen","year":"2024","unstructured":"Chen, D. et al. Liraglutide enhances the effect of checkpoint blockade in lung and liver cancers through the inhibition of neutrophil extracellular traps. FEBS Open Bio. 14, 1365\u20131377 (2024).","journal-title":"FEBS Open Bio."},{"key":"2810_CR284","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.4049\/jimmunol.1601011","volume":"198","author":"HJ Fischer","year":"2017","unstructured":"Fischer, H. J. et al. The insulin receptor plays a critical role in T cell function and adaptive immunity. J. Immunol. 198, 1910\u20131920 (2017).","journal-title":"J. Immunol."},{"key":"2810_CR285","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1128\/MCB.00319-13","volume":"33","author":"N Patsoukis","year":"2013","unstructured":"Patsoukis, N. et al. PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2. Mol. Cell. Biol. 33, 3091\u20133098 (2013).","journal-title":"Mol. Cell. Biol."},{"key":"2810_CR286","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.coi.2018.10.005","volume":"56","author":"E Dalmas","year":"2019","unstructured":"Dalmas, E. Innate immune priming of insulin secretion. Curr. Opin. Immunol. 56, 44\u201349 (2019).","journal-title":"Curr. Opin. Immunol."},{"key":"2810_CR287","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature01621","volume":"423","author":"H Ueda","year":"2003","unstructured":"Ueda, H. et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423, 506\u2013511 (2003).","journal-title":"Nature"},{"key":"2810_CR288","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1210\/jc.2005-1407","volume":"91","author":"H Ikegami","year":"2006","unstructured":"Ikegami, H. et al. The association of CTLA4 polymorphism with type 1 diabetes is concentrated in patients complicated with autoimmune thyroid disease: a multicenter collaborative study in Japan. J. Clin. Endocrinol. Metab. 91, 1087\u20131092 (2006).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2810_CR289","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.gene.2012.07.044","volume":"508","author":"ST Tang","year":"2012","unstructured":"Tang, S. T. et al. Association of cytotoxic T-lymphocyte associated antigen 4 gene polymorphism with type 1 diabetes mellitus: a meta-analysis. Gene 508, 165\u2013187 (2012).","journal-title":"Gene"},{"key":"2810_CR290","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/sj.gene.6363933","volume":"4","author":"L Bouqbis","year":"2003","unstructured":"Bouqbis, L. et al. Association of the CTLA4 promoter region (-1661G allele) with type 1 diabetes in the South Moroccan population. Genes Immun. 4, 132\u2013137 (2003).","journal-title":"Genes Immun."},{"key":"2810_CR291","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1189\/jlb.0904524","volume":"77","author":"R Bergholdt","year":"2005","unstructured":"Bergholdt, R. et al. CBLB variants in type 1 diabetes and their genetic interaction with CTLA4. J. Leukoc. Biol. 77, 579\u2013585 (2005).","journal-title":"J. Leukoc. Biol."},{"key":"2810_CR292","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nature05911","volume":"447","author":"Wellcome Trust Case Control Consortium","year":"2007","unstructured":"Wellcome Trust Case Control Consortium Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661\u2013678 (2007).","journal-title":"Nature"},{"key":"2810_CR293","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.2337\/db10-0076","volume":"59","author":"F Pociot","year":"2010","unstructured":"Pociot, F. et al. Genetics of type 1 diabetes: what\u2019s next? Diabetes 59, 1561\u20131571 (2010).","journal-title":"Diabetes"},{"key":"2810_CR294","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1093\/cei\/uxad002","volume":"211","author":"J Vandewalle","year":"2023","unstructured":"Vandewalle, J. et al. CTLA4, SH2B3, and CLEC16A diversely affect the progression of early islet autoimmunity in relatives of Type 1 diabetes patients. Clin. Exp. Immunol. 211, 224\u2013232 (2023).","journal-title":"Clin. Exp. Immunol."},{"key":"2810_CR295","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.2337\/dc12-2284","volume":"36","author":"AM Valdes","year":"2013","unstructured":"Valdes, A. M., Varney, M. D., Erlich, H. A. & Noble, J. A. Receiver operating characteristic analysis of HLA, CTLA4, and insulin genotypes for type 1 diabetes. Diab. Care 36, 2504\u20132507 (2013).","journal-title":"Diab. Care"},{"key":"2810_CR296","first-page":"683","volume":"14","author":"SY Luo","year":"2012","unstructured":"Luo, S. Y. et al. [Association of cytotoxic T lymphocyte-associated antigen-4+49A\/G polymorphism with childhood type 1 diabetes mellitus: a meta-analysis]. Zhongguo Dang Dai Er Ke Za Zhi 14, 683\u2013688 (2012).","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"2810_CR297","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/1753-0407.12192","volume":"7","author":"A Rodr\u00edguez","year":"2015","unstructured":"Rodr\u00edguez, A., Alfaro, J. M., Balthazar, V. & Pineda Trujillo, N. Association analysis of PTPN22, CTLA4 and IFIH1 genes with type 1 diabetes in Colombian families. J. Diab. 7, 402\u2013410 (2015).","journal-title":"J. Diab."},{"key":"2810_CR298","doi-asserted-by":"publisher","first-page":"40","DOI":"10.4274\/Jcrpe.879","volume":"5","author":"F \u00c7elmeli","year":"2013","unstructured":"\u00c7elmeli, F. et al. CTLA-4 (+49A\/G) polymorphism and type-1 diabetes in Turkish children. J. Clin. Res. Pediatr. Endocrinol. 5, 40\u201343 (2013).","journal-title":"J. Clin. Res. Pediatr. Endocrinol."},{"key":"2810_CR299","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2404661121","volume":"121","author":"S Mok","year":"2024","unstructured":"Mok, S. et al. Post-immunotherapy CTLA-4 Ig treatment improves antitumor efficacy. Proc. Natl. Acad. Sci. USA 121, e2404661121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2810_CR300","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106147","volume":"178","author":"MA Khan","year":"2022","unstructured":"Khan, M. A. et al. CTLA4-Ig mediated immunosuppression favors immunotolerance and restores graft in mouse airway transplants. Pharm. Res. 178, 106147 (2022).","journal-title":"Pharm. Res."},{"key":"2810_CR301","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1084\/jem.178.5.1801","volume":"178","author":"H Lin","year":"1993","unstructured":"Lin, H. et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J. Exp. Med. 178, 1801\u20131806 (1993).","journal-title":"J. Exp. Med."},{"key":"2810_CR302","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/381434a0","volume":"381","author":"CP Larsen","year":"1996","unstructured":"Larsen, C. P. et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381, 434\u2013438 (1996).","journal-title":"Nature"},{"key":"2810_CR303","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1399-3089.2011.00627.x","volume":"18","author":"C Zhai","year":"2011","unstructured":"Zhai, C. et al. Porcine CTLA4-Ig prolong islet xenografts in rats by downregulating the direct pathway of T-cell activation. Xenotransplantation 18, 40\u201345 (2011).","journal-title":"Xenotransplantation"},{"key":"2810_CR304","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00125-015-3766-6","volume":"59","author":"R Bassi","year":"2016","unstructured":"Bassi, R., Fornoni, A., Doria, A. & Fiorina, P. CTLA4-Ig in B7-1-positive diabetic and non-diabetic kidney disease. Diabetologia 59, 21\u201329 (2016).","journal-title":"Diabetologia"},{"key":"2810_CR305","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1111\/ajt.12838","volume":"14","author":"R Pawlick","year":"2014","unstructured":"Pawlick, R. et al. The combination of anti-NKG2D and CTLA-4 Ig therapy prolongs islet allograft survival in a murine model. Am. J. Transpl. 14, 2367\u20132374 (2014).","journal-title":"Am. J. Transpl."},{"key":"2810_CR306","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.4049\/jimmunol.158.5.2285","volume":"158","author":"CA Hunter","year":"1997","unstructured":"Hunter, C. A. et al. The role of the CD28\/B7 interaction in the regulation of NK cell responses during infection with Toxoplasma gondii. J. Immunol. 158, 2285\u20132293 (1997).","journal-title":"J. Immunol."},{"key":"2810_CR307","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.0105-2896.2010.00893.x","volume":"235","author":"M Champsaur","year":"2010","unstructured":"Champsaur, M. & Lanier, L. L. Effect of NKG2D ligand expression on host immune responses. Immunol. Rev. 235, 267\u2013285 (2010).","journal-title":"Immunol. Rev."},{"key":"2810_CR308","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/art.10294","volume":"46","author":"LW Moreland","year":"2002","unstructured":"Moreland, L. W. et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 46, 1470\u20131479 (2002).","journal-title":"Arthritis Rheum."},{"key":"2810_CR309","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1080\/13543784.2024.2326036","volume":"33","author":"E Maddaloni","year":"2024","unstructured":"Maddaloni, E. et al. Immune checkpoint modulators in early clinical development for the treatment of type 1 diabetes. Expert Opin. Investig. Drugs 33, 303\u2013318 (2024).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"2810_CR310","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S0140-6736(11)60886-6","volume":"378","author":"T Orban","year":"2011","unstructured":"Orban, T. et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 378, 412\u2013419 (2011).","journal-title":"Lancet"},{"key":"2810_CR311","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/dme.12159","volume":"30","author":"AG Jones","year":"2013","unstructured":"Jones, A. G. & Hattersley, A. T. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabetes Med. 30, 803\u2013817 (2013).","journal-title":"Diabetes Med."},{"key":"2810_CR312","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.2337\/dc13-0604","volume":"37","author":"T Orban","year":"2014","unstructured":"Orban, T. et al. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care 37, 1069\u20131075 (2014).","journal-title":"Diabetes Care"},{"key":"2810_CR313","doi-asserted-by":"publisher","first-page":"e2023739118","DOI":"10.1073\/pnas.2023739118","volume":"118","author":"M Tekguc","year":"2021","unstructured":"Tekguc, M. et al. Treg-expressed CTLA-4 depletes CD80\/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells. Proc. Natl. Acad. Sci. USA 118, e2023739118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2810_CR314","doi-asserted-by":"publisher","first-page":"585917","DOI":"10.1155\/2015\/585917","volume":"2015","author":"M Khodaeian","year":"2015","unstructured":"Khodaeian, M., Enayati, S., Tabatabaei-Malazy, O. & Amoli, M. M. Association between genetic variants and diabetes mellitus in iranian populations: a systematic review of observational studies. J. Diabetes Res. 2015, 585917 (2015).","journal-title":"J. Diabetes Res."},{"key":"2810_CR315","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.2147\/DMSO.S374451","volume":"15","author":"D Ren","year":"2022","unstructured":"Ren, D., He, L. & Pang, X. Association of CLTA-4 gene polymorphisms with diabetes mellitus: a study based on the Han population of Northern China. Diabetes Metab. Syndr. Obes. 15, 2705\u20132712 (2022).","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"2810_CR316","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11892-019-1143-4","volume":"19","author":"F Bonacina","year":"2019","unstructured":"Bonacina, F., Baragetti, A., Catapano, A. L. & Norata, G. D. The interconnection between immuno-metabolism, diabetes, and CKD. Curr. Diab Rep. 19, 21 (2019).","journal-title":"Curr. Diab Rep."},{"key":"2810_CR317","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.immuni.2015.08.023","volume":"43","author":"GD Norata","year":"2015","unstructured":"Norata, G. D. et al. The cellular and molecular basis of translational immunometabolism. Immunity 43, 421\u2013434 (2015).","journal-title":"Immunity"},{"key":"2810_CR318","doi-asserted-by":"publisher","first-page":"115404","DOI":"10.1016\/j.ejca.2025.115404","volume":"221","author":"M Fortuny","year":"2025","unstructured":"Fortuny, M. et al. Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: influence of comorbidities and clinical outcomes. Eur. J. Cancer 221, 115404 (2025).","journal-title":"Eur. J. Cancer"},{"key":"2810_CR319","doi-asserted-by":"publisher","first-page":"1396022","DOI":"10.3389\/fendo.2024.1396022","volume":"15","author":"YY Zhang","year":"2024","unstructured":"Zhang, Y. Y. et al. Effects of T2DM on cancer progression: pivotal precipitating factors and underlying mechanisms. Front. Endocrinol. (Lausanne) 15, 1396022 (2024).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"2810_CR320","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1158\/1055-9965.EPI-20-1245","volume":"30","author":"J Pearson-Stuttard","year":"2021","unstructured":"Pearson-Stuttard, J. et al. Type 2 diabetes and cancer: an umbrella review of observational and Mendelian randomization studies. Cancer Epidemiol. Biomark. Prev. 30, 1218\u20131228 (2021).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"2810_CR321","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.diabres.2005.03.002","volume":"68","author":"I Tk\u00e1c","year":"2005","unstructured":"Tk\u00e1c, I. Metabolic syndrome in relationship to type 2 diabetes and atherosclerosis. Diabetes Res. Clin. Pract. 68, S2\u2013S9 (2005).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"2810_CR322","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202500755RR","volume":"39","author":"Q Li","year":"2025","unstructured":"Li, Q. et al. p53 Modulates the gut-\u2013liver axis via PI3K\/AKT\/Wnt signaling pathways in type 2 diabetes. FASEB J. 39, e70898 (2025).","journal-title":"FASEB J."},{"key":"2810_CR323","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/imm.13404","volume":"165","author":"Y Liang","year":"2022","unstructured":"Liang, Y. et al. IL-33 activates mTORC1 and modulates glycolytic metabolism in CD8(+) T cells. Immunology 165, 61\u201373 (2022).","journal-title":"Immunology"},{"key":"2810_CR324","first-page":"69","volume":"47","author":"SG Ward","year":"1999","unstructured":"Ward, S. G. The complexities of CD28 and CTLA-4 signalling: PI3K and beyond. Arch. Immunol. Ther. Exp. 47, 69\u201375 (1999).","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"2810_CR325","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.25122\/jml-2023-0163","volume":"16","author":"N Abdullah","year":"2023","unstructured":"Abdullah, N., Al-Mansouri, L., Ali, N. & Hadi, N. R. Molecular and serological biomarkers to predict trastuzumab responsiveness in HER-2 positive breast cancer. J. Med. Life 16, 1633\u20131638 (2023).","journal-title":"J. Med. Life"},{"key":"2810_CR326","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41392-023-01376-w","volume":"8","author":"R Ruze","year":"2023","unstructured":"Ruze, R. et al. Mechanisms of obesity- and diabetes mellitus-related pancreatic carcinogenesis: a comprehensive and systematic review. Signal Transduct. Target. Ther. 8, 139 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2810_CR327","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/jdi.12609","volume":"8","author":"J Lu","year":"2017","unstructured":"Lu, J. et al. Chronic hepatitis B virus infection status is more prevalent in patients with type 2 diabetes. J. Diabetes Investig. 8, 619\u2013625 (2017).","journal-title":"J. Diabetes Investig."},{"key":"2810_CR328","doi-asserted-by":"publisher","first-page":"53","DOI":"10.17305\/bjbms.2022.7525","volume":"23","author":"W He","year":"2023","unstructured":"He, W. et al. Circulating cytokine profile and modulation of regulatory T cells in chronic hepatitis B patients with type 2 diabetes mellitus. Biomol. Biomed. 23, 53\u201362 (2023).","journal-title":"Biomol. Biomed."},{"key":"2810_CR329","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-071934","volume":"13","author":"X Wang","year":"2023","unstructured":"Wang, X., Chen, J., Cao, Z. & Yu, X. Associations between human cytomegalovirus infection and type 2 diabetes mellitus: a systematic review and meta-analysis. BMJ Open 13, e071934 (2023).","journal-title":"BMJ Open"},{"key":"2810_CR330","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.4049\/jimmunol.176.4.2645","volume":"176","author":"SR Hadrup","year":"2006","unstructured":"Hadrup, S. R. et al. Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly. J. Immunol. 176, 2645\u20132653 (2006).","journal-title":"J. Immunol."},{"key":"2810_CR331","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.3390\/biomedicines10092089","volume":"10","author":"C Rey-Re\u00f1ones","year":"2022","unstructured":"Rey-Re\u00f1ones, C. et al. Type 2 diabetes mellitus and COVID-19: a narrative review. Biomedicines 10, 2089 (2022).","journal-title":"Biomedicines"},{"key":"2810_CR332","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12933-020-01047-y","volume":"19","author":"C Sardu","year":"2020","unstructured":"Sardu, C. et al. Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19. Cardiovasc. Diabetol. 19, 76 (2020).","journal-title":"Cardiovasc. Diabetol."},{"key":"2810_CR333","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ccell.2022.04.004","volume":"40","author":"Y Hailemichael","year":"2022","unstructured":"Hailemichael, Y. et al. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell 40, 509\u2013523.e506 (2022).","journal-title":"Cancer Cell"},{"key":"2810_CR334","doi-asserted-by":"publisher","first-page":"108889","DOI":"10.1016\/j.intimp.2022.108889","volume":"109","author":"EE Abd El-Fattah","year":"2022","unstructured":"Abd El-Fattah, E. E. & Zakaria, A. Y. Metformin modulate immune fitness in hepatocellular carcinoma: molecular and cellular approach. Int. Immunopharmacol. 109, 108889 (2022).","journal-title":"Int. Immunopharmacol."},{"key":"2810_CR335","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ebiom.2017.10.009","volume":"25","author":"Y Kunisada","year":"2017","unstructured":"Kunisada, Y. et al. Attenuation of CD4(+)CD25(+) regulatory T cells in the tumor microenvironment by metformin, a type 2 diabetes drug. EBioMedicine. 25, 154\u2013164 (2017).","journal-title":"EBioMedicine."},{"key":"2810_CR336","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1158\/1078-0432.CCR-22-3116","volume":"29","author":"A Cortellini","year":"2023","unstructured":"Cortellini, A. et al. Type 2 diabetes mellitus and efficacy outcomes from immune checkpoint blockade in patients with cancer. Clin. Cancer Res. 29, 2714\u20132724 (2023).","journal-title":"Clin. Cancer Res."},{"key":"2810_CR337","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/j.jtho.2019.07.020","volume":"14","author":"S Yendamuri","year":"2019","unstructured":"Yendamuri, S. et al. Body mass index influences the salutary effects of metformin on survival after lobectomy for stage I NSCLC. J. Thorac. Oncol. 14, 2181\u20132187 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"2810_CR338","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.intimp.2014.06.033","volume":"22","author":"L Szablewski","year":"2014","unstructured":"Szablewski, L. Role of immune system in type 1 diabetes mellitus pathogenesis. Int. Immunopharmacol. 22, 182\u2013191 (2014).","journal-title":"Int. Immunopharmacol."},{"key":"2810_CR339","doi-asserted-by":"publisher","first-page":"442","DOI":"10.2174\/1573399815666191024085838","volume":"16","author":"A Berbudi","year":"2020","unstructured":"Berbudi, A., Rahmadika, N., Tjahjadi, A. I. & Ruslami, R. Type 2 diabetes and its impact on the immune system. Curr. Diab. Rev. 16, 442\u2013449 (2020).","journal-title":"Curr. Diab. Rev."},{"key":"2810_CR340","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","volume":"40","author":"LS Chang","year":"2019","unstructured":"Chang, L. S. et al. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr. Rev. 40, 17\u201365 (2019).","journal-title":"Endocr. Rev."},{"key":"2810_CR341","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-22-0689","volume":"187","author":"ES Husebye","year":"2022","unstructured":"Husebye, E. S. et al. Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur. J. Endocrinol. 187, G1\u2013g21 (2022).","journal-title":"Eur. J. Endocrinol."},{"key":"2810_CR342","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/annonc\/mdy551","volume":"30","author":"KM Heinhuis","year":"2019","unstructured":"Heinhuis, K. M. et al. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann. Oncol. 30, 219\u2013235 (2019).","journal-title":"Ann. Oncol."},{"key":"2810_CR343","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.ccell.2017.05.010","volume":"31","author":"G Abril-Rodriguez","year":"2017","unstructured":"Abril-Rodriguez, G. & Ribas, A. SnapShot: Immune Checkpoint Inhibitors. Cancer Cell 31, 848\u2013848.e841 (2017).","journal-title":"Cancer Cell"},{"key":"2810_CR344","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nri2787","volume":"10","author":"A Lehuen","year":"2010","unstructured":"Lehuen, A., Diana, J., Zaccone, P. & Cooke, A. Immune cell crosstalk in type 1 diabetes. Nat. Rev. Immunol. 10, 501\u2013513 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"2810_CR345","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.immuni.2009.08.023","volume":"31","author":"M Feuerer","year":"2009","unstructured":"Feuerer, M. et al. How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets. Immunity 31, 654\u2013664 (2009).","journal-title":"Immunity"},{"key":"2810_CR346","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nature14468","volume":"523","author":"EF McKinney","year":"2015","unstructured":"McKinney, E. F. et al. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature 523, 612\u2013616 (2015).","journal-title":"Nature"},{"key":"2810_CR347","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.4049\/jimmunol.1100714","volume":"187","author":"M Bettini","year":"2011","unstructured":"Bettini, M. et al. Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3. J. Immunol. 187, 3493\u20133498 (2011).","journal-title":"J. Immunol."},{"key":"2810_CR348","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1084\/jem.20100466","volume":"208","author":"T Okazaki","year":"2011","unstructured":"Okazaki, T. et al. PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J. Exp. Med. 208, 395\u2013407 (2011).","journal-title":"J. Exp. Med."},{"key":"2810_CR349","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.immuni.2022.03.013","volume":"55","author":"T Maruhashi","year":"2022","unstructured":"Maruhashi, T. et al. Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity. Immunity 55, 912\u2013924.e918 (2022).","journal-title":"Immunity"},{"key":"2810_CR350","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04607-4","volume":"21","author":"D Mallardo","year":"2023","unstructured":"Mallardo, D. et al. The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab. J. Transl. Med. 21, 753 (2023).","journal-title":"J. Transl. Med."},{"key":"2810_CR351","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.annonc.2022.01.007","volume":"33","author":"D Mallardo","year":"2022","unstructured":"Mallardo, D. et al. Concomitant type 2 diabetes mellitus (T2DM) in metastatic melanoma patients could be related to lower level of LAG-3: a transcriptomic analysis of a retrospective cohort. Ann. Oncol. 33, 445\u2013447 (2022).","journal-title":"Ann. Oncol."},{"key":"2810_CR352","doi-asserted-by":"publisher","first-page":"594","DOI":"10.4049\/jimmunol.2100850","volume":"208","author":"BE Jones","year":"2022","unstructured":"Jones, B. E. et al. Fewer LAG-3(+) T cells in relapsing-remitting multiple sclerosis and type 1 diabetes. J. Immunol. 208, 594\u2013602 (2022).","journal-title":"J. Immunol."},{"key":"2810_CR353","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","volume":"20","author":"Y Wolf","year":"2020","unstructured":"Wolf, Y., Anderson, A. C. & Kuchroo, V. K. TIM3 comes of age as an inhibitory receptor. Nat. Rev. Immunol. 20, 173\u2013185 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"2810_CR354","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.937109","volume":"13","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. Altered expression of Tim family molecules and an imbalanced ratio of Tim-3 to Tim-1 expression in patients with type 1 diabetes. Front. Endocrinol. (Lausanne) 13, 937109 (2022).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"2810_CR355","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.852436","volume":"13","author":"H Wang","year":"2022","unstructured":"Wang, H. et al. Tim-3 expression causes NK cell dysfunction in type 2 diabetes patients. Front. Immunol. 13, 852436 (2022).","journal-title":"Front. Immunol."},{"key":"2810_CR356","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/jdi.12523","volume":"7","author":"WJ Yan","year":"2016","unstructured":"Yan, W. J. et al. T cell immunoglobulin and mucin domain-containing molecule 3 on CD14(+) monocytes serves as a novel biological marker for diabetes duration in type 2 diabetes mellitus. J. Diabetes Investig. 7, 867\u2013873 (2016).","journal-title":"J. Diabetes Investig."},{"key":"2810_CR357","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/2583257","volume":"2020","author":"L Sun","year":"2020","unstructured":"Sun, L. et al. Circulating T cells exhibit different TIM3\/Galectin-9 expression in patients with obesity and obesity-related diabetes. J. Diabetes Res. 2020, 2583257 (2020).","journal-title":"J. Diabetes Res."},{"key":"2810_CR358","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.molimm.2018.02.006","volume":"95","author":"J Sun","year":"2018","unstructured":"Sun, J. et al. miR-330-5p\/Tim-3 axis regulates macrophage M2 polarization and insulin resistance in diabetes mice. Mol. Immunol. 95, 107\u2013113 (2018).","journal-title":"Mol. Immunol."},{"key":"2810_CR359","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/nri1111","volume":"3","author":"VK Kuchroo","year":"2003","unstructured":"Kuchroo, V. K., Umetsu, D. T., DeKruyff, R. H. & Freeman, G. J. The TIM gene family: emerging roles in immunity and disease. Nat. Rev. Immunol. 3, 454\u2013462 (2003).","journal-title":"Nat. Rev. Immunol."},{"key":"2810_CR360","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1210\/en.2011-1579","volume":"153","author":"M Kanzaki","year":"2012","unstructured":"Kanzaki, M. et al. Galectin-9 and T cell immunoglobulin mucin-3 pathway is a therapeutic target for type 1 diabetes. Endocrinology 153, 612\u2013620 (2012).","journal-title":"Endocrinology"},{"key":"2810_CR361","doi-asserted-by":"publisher","first-page":"31319","DOI":"10.1073\/pnas.2019743117","volume":"117","author":"H Hu","year":"2020","unstructured":"Hu, H., Zakharov, P. N., Peterson, O. J. & Unanue, E. R. Cytocidal macrophages in symbiosis with CD4 and CD8 T cells cause acute diabetes following checkpoint blockade of PD-1 in NOD mice. Proc. Natl. Acad. Sci. USA 117, 31319\u201331330 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2810_CR362","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2315419121","volume":"121","author":"C Selck","year":"2024","unstructured":"Selck, C. et al. Extraislet expression of islet antigen boosts T cell exhaustion to partially prevent autoimmune diabetes. Proc. Natl. Acad. Sci. USA 121, e2315419121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2810_CR363","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1370907","volume":"15","author":"P Trivedi","year":"2024","unstructured":"Trivedi, P. et al. TIGIT acts as an immune checkpoint upon inhibition of PD1 signaling in autoimmune diabetes. Front. Immunol. 15, 1370907 (2024).","journal-title":"Front. Immunol."},{"key":"2810_CR364","doi-asserted-by":"publisher","first-page":"e124427","DOI":"10.1172\/jci.insight.124427","volume":"4","author":"LE Lucca","year":"2019","unstructured":"Lucca, L. E. et al. TIGIT signaling restores suppressor function of Th1 Tregs. JCI Insight 4, e124427 (2019).","journal-title":"JCI Insight"},{"key":"2810_CR365","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53264-8","volume":"15","author":"T Zhong","year":"2024","unstructured":"Zhong, T. et al. TGF-\u03b2-mediated crosstalk between TIGIT(+) Tregs and CD226(+)CD8(+) T cells in the progression and remission of type 1 diabetes. Nat. Commun. 15, 8894 (2024).","journal-title":"Nat. Commun."},{"key":"2810_CR366","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.immuni.2014.02.012","volume":"40","author":"N Joller","year":"2014","unstructured":"Joller, N. et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity 40, 569\u2013581 (2014).","journal-title":"Immunity"},{"key":"2810_CR367","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.immuni.2020.09.006","volume":"53","author":"M Weulersse","year":"2020","unstructured":"Weulersse, M. et al. Eomes-dependent loss of the co-activating receptor CD226 restrains CD8(+) T cell anti-tumor functions and limits the efficacy of cancer immunotherapy. Immunity 53, 824\u2013839.e810 (2020).","journal-title":"Immunity"},{"key":"2810_CR368","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.3389\/fimmu.2020.02180","volume":"11","author":"MR Shapiro","year":"2020","unstructured":"Shapiro, M. R. et al. CD226 deletion reduces type 1 diabetes in the NOD mouse by impairing thymocyte development and peripheral T cell activation. Front. Immunol. 11, 2180 (2020).","journal-title":"Front. Immunol."},{"key":"2810_CR369","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.humimm.2012.10.009","volume":"74","author":"ZX Qiu","year":"2013","unstructured":"Qiu, Z. X. et al. CD226 Gly307Ser association with multiple autoimmune diseases: a meta-analysis. Hum. Immunol. 74, 249\u2013255 (2013).","journal-title":"Hum. Immunol."},{"key":"2810_CR370","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.imlet.2020.06.003","volume":"225","author":"M Hoseini-Aghdam","year":"2020","unstructured":"Hoseini-Aghdam, M. et al. Enhanced expression of TIGIT but not neuropilin-1 in patients with type 2 diabetes mellitus. Immunol. Lett. 225, 1\u20138 (2020).","journal-title":"Immunol. Lett."},{"key":"2810_CR371","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s11154-016-9395-7","volume":"18","author":"P Iglesias","year":"2017","unstructured":"Iglesias, P., Bajo, M. A., Selgas, R. & D\u00edez, J. J. Thyroid dysfunction and kidney disease: an update. Rev. Endocr. Metab. Disord. 18, 131\u2013144 (2017).","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"2810_CR372","doi-asserted-by":"publisher","first-page":"179","DOI":"10.5694\/mja16.00545","volume":"205","author":"JP Walsh","year":"2016","unstructured":"Walsh, J. P. Managing thyroid disease in general practice. Med. J. Aust. 205, 179\u2013184 (2016).","journal-title":"Med. J. Aust."},{"key":"2810_CR373","doi-asserted-by":"publisher","first-page":"e250004","DOI":"10.1530\/ETJ-25-0004","volume":"14","author":"MT Neset","year":"2025","unstructured":"Neset, M. T. et al. Insight into the metabolic shifts in Graves\u2019 hyperthyroidism: a study of acylcarnitine and lipid profiles. Eur. Thyroid J. 14, e250004 (2025).","journal-title":"Eur. Thyroid J."},{"key":"2810_CR374","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12020-023-03420-9","volume":"84","author":"J Jonklaas","year":"2024","unstructured":"Jonklaas, J. Hypothyroidism, lipids, and lipidomics. Endocrine 84, 293\u2013300 (2024).","journal-title":"Endocrine"},{"key":"2810_CR375","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s12020-020-02188-6","volume":"68","author":"A Weetman","year":"2020","unstructured":"Weetman, A. Autoimmune thyroid disease. Endocrine 68, 258\u2013260 (2020).","journal-title":"Endocrine"},{"key":"2810_CR376","doi-asserted-by":"publisher","first-page":"101388","DOI":"10.1016\/j.beem.2020.101388","volume":"34","author":"A Antonelli","year":"2020","unstructured":"Antonelli, A. et al. Graves\u2019 disease: clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy. Best. Pract. Res. Clin. Endocrinol. Metab. 34, 101388 (2020).","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"2810_CR377","doi-asserted-by":"publisher","first-page":"4703","DOI":"10.3390\/ijms25094703","volume":"25","author":"E Tywanek","year":"2024","unstructured":"Tywanek, E., Michalak, A., \u015awirska, J. & Zwolak, A. Autoimmunity, new potential biomarkers and the thyroid gland-the perspective of Hashimoto\u2019s thyroiditis and its treatment. Int. J. Mol. Sci. 25, 4703 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2810_CR378","doi-asserted-by":"crossref","unstructured":"Grimm, D. The fight against cancer by microgravity: the multicellular spheroid as a metastasis model. Int. J. Mol. Sci. 23, 3073 (2022).","DOI":"10.3390\/ijms23063073"},{"key":"2810_CR379","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3803\/EnM.2022.1553","volume":"37","author":"CK Jung","year":"2022","unstructured":"Jung, C. K., Bychkov, A. & Kakudo, K. Update from the 2022 World Health Organization classification of thyroid tumors: a standardized diagnostic approach. Endocrinol. Metab. (Seoul) 37, 703\u2013718 (2022).","journal-title":"Endocrinol. Metab. (Seoul)"},{"key":"2810_CR380","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","volume":"33","author":"ZW Baloch","year":"2022","unstructured":"Baloch, Z. W. et al. Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocr. Pathol. 33, 27\u201363 (2022).","journal-title":"Endocr. Pathol."},{"key":"2810_CR381","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1080\/08916934.2021.1946796","volume":"54","author":"M Kawabata","year":"2021","unstructured":"Kawabata, M. et al. PD-1 gene polymorphisms and thyroid expression of PD-1 ligands differ between Graves\u2019 and Hashimoto\u2019s diseases. Autoimmunity 54, 450\u2013459 (2021).","journal-title":"Autoimmunity"},{"key":"2810_CR382","doi-asserted-by":"publisher","first-page":"102285","DOI":"10.1016\/j.jaut.2019.05.013","volume":"103","author":"D \u00c1lvarez-Sierra","year":"2019","unstructured":"\u00c1lvarez-Sierra, D. et al. Analysis of the PD-1\/PD-L1 axis in human autoimmune thyroid disease: insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity. J. Autoimmun. 103, 102285 (2019).","journal-title":"J. Autoimmun."},{"key":"2810_CR383","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12022-018-9540-9","volume":"29","author":"D Lubin","year":"2018","unstructured":"Lubin, D. et al. Papillary thyroid carcinoma emerging from Hashimoto thyroiditis demonstrates increased PD-L1 expression, which persists with metastasis. Endocr. Pathol. 29, 317\u2013323 (2018).","journal-title":"Endocr. Pathol."},{"key":"2810_CR384","doi-asserted-by":"publisher","first-page":"dgaa569","DOI":"10.1210\/clinem\/dgaa569","volume":"105","author":"AC Ortega-Rodr\u00edguez","year":"2020","unstructured":"Ortega-Rodr\u00edguez, A. C. et al. Quantitative and functional analysis of PD-1+ NK cells in patients with autoimmune thyroid disease. J. Clin. Endocrinol. Metab. 105, dgaa569 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2810_CR385","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1089\/thy.2021.0694","volume":"32","author":"D \u00c1lvarez-Sierra","year":"2022","unstructured":"\u00c1lvarez-Sierra, D. et al. Lymphocytic thyroiditis transcriptomic profiles support the role of checkpoint pathways and B cells in pogenesis. Thyroid 32, 682\u2013693 (2022).","journal-title":"Thyroid"},{"key":"2810_CR386","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/apm.13218","volume":"130","author":"E Pakkanen","year":"2022","unstructured":"Pakkanen, E. et al. PD-L1 and PD-1 expression in thyroid follicular epithelial dysplasia: Hashimoto thyroiditis related atypia and potential papillary carcinoma precursor. Apmis 130, 276\u2013283 (2022).","journal-title":"Apmis"},{"key":"2810_CR387","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","volume":"83","author":"I de Bruijn","year":"2023","unstructured":"de Bruijn, I. et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR Project Genie Biopharma Collaborative in cBioPortal. Cancer Res. 83, 3861\u20133867 (2023).","journal-title":"Cancer Res."},{"key":"2810_CR388","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2023.111931","volume":"570","author":"DE Zantut-Wittmann","year":"2023","unstructured":"Zantut-Wittmann, D. E. et al. PD-L1 and MCL-1 markers and the relationship with prognostic characteristics of differentiated thyroid carcinoma. Mol. Cell. Endocrinol. 570, 111931 (2023).","journal-title":"Mol. Cell. Endocrinol."},{"key":"2810_CR389","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1530\/ERC-16-0421","volume":"24","author":"S Ahn","year":"2017","unstructured":"Ahn, S. et al. Comprehensive screening for PD-L1 expression in thyroid cancer. Endocr. Relat. Cancer 24, 97\u2013106 (2017).","journal-title":"Endocr. Relat. Cancer"},{"key":"2810_CR390","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.pathol.2019.11.007","volume":"52","author":"M Fadia","year":"2020","unstructured":"Fadia, M. et al. PD-L1 expression in papillary thyroid cancer with and without lymphocytic thyroiditis: a cross sectional study. Pathology 52, 318\u2013322 (2020).","journal-title":"Pathology"},{"key":"2810_CR391","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ejso.2018.10.060","volume":"45","author":"Y Bi","year":"2019","unstructured":"Bi, Y. et al. PD-1\/PD-L1 expressions in medullary thyroid carcinoma: clinicopathologic and prognostic analysis of Chinese population. Eur. J. Surg. Oncol. 45, 353\u2013358 (2019).","journal-title":"Eur. J. Surg. Oncol."},{"key":"2810_CR392","first-page":"328","volume":"33","author":"SS Herr","year":"1995","unstructured":"Herr, S. S. A humanist\u2019s legacy: Burton Blatt and the origins of the disability rights movement. Ment. Retard. 33, 328\u2013331 (1995).","journal-title":"Ment. Retard."},{"key":"2810_CR393","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13046-020-01818-1","volume":"40","author":"F Liotti","year":"2021","unstructured":"Liotti, F. et al. PD-1 blockade delays tumor growth by inhibiting an intrinsic SHP2\/Ras\/MAPK signalling in thyroid cancer cells. J. Exp. Clin. Cancer Res. 40, 22 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2810_CR394","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 378, 158\u2013168 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2810_CR395","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ejca.2020.11.010","volume":"144","author":"C Robert","year":"2021","unstructured":"Robert, C. et al. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: a landmark analysis in patients with advanced melanoma. Eur. J. Cancer 144, 182\u2013191 (2021).","journal-title":"Eur. J. Cancer"},{"key":"2810_CR396","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","volume":"4","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa, R. et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 4, 173\u2013182 (2018).","journal-title":"JAMA Oncol."},{"key":"2810_CR397","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1007\/s10238-023-01082-5","volume":"23","author":"A Nervo","year":"2023","unstructured":"Nervo, A. et al. Immune-related thyroid dysfunctions during anti PD-1\/PD-L1 inhibitors: new evidence from a single centre experience. Clin. Exp. Med. 23, 4817\u20134824 (2023).","journal-title":"Clin. Exp. Med."},{"key":"2810_CR398","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27077","volume":"10","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Thyroid dysfunction (TD) induced by PD-1\/PD-L1 inhibitors in advanced lung cancer. Heliyon 10, e27077 (2024).","journal-title":"Heliyon"},{"key":"2810_CR399","first-page":"41","volume":"80","author":"T Yanagawa","year":"1995","unstructured":"Yanagawa, T. et al. CTLA-4 gene polymorphism associated with Graves\u2019 disease in a Caucasian population. J. Clin. Endocrinol. Metab. 80, 41\u201345 (1995).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2810_CR400","first-page":"143","volume":"82","author":"H Donner","year":"1997","unstructured":"Donner, H. et al. CTLA4 alanine-17 confers genetic susceptibility to Graves\u2019 disease and to type 1 diabetes mellitus. J. Clin. Endocrinol. Metab. 82, 143\u2013146 (1997).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2810_CR401","first-page":"2398","volume":"84","author":"JM Heward","year":"1999","unstructured":"Heward, J. M. et al. The development of Graves\u2019 disease and the CTLA-4 gene on chromosome 2q33. J. Clin. Endocrinol. Metab. 84, 2398\u20132401 (1999).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2810_CR402","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s10038-003-0120-5","volume":"49","author":"K Furugaki","year":"2004","unstructured":"Furugaki, K. et al. Association of the T-cell regulatory gene CTLA4 with Graves\u2019 disease and autoimmune thyroid disease in the Japanese. J. Hum. Genet 49, 166\u2013168 (2004).","journal-title":"J. Hum. Genet"},{"key":"2810_CR403","doi-asserted-by":"publisher","DOI":"10.1186\/s12881-018-0665-y","volume":"19","author":"X Chen","year":"2018","unstructured":"Chen, X. et al. Correlation between CTLA-4 and CD40 gene polymorphisms and their interaction in Graves\u2019 disease in a Chinese Han population. BMC Med Genet 19, 171 (2018).","journal-title":"BMC Med Genet"},{"key":"2810_CR404","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1093\/hmg\/8.7.1195","volume":"8","author":"B Vaidya","year":"1999","unstructured":"Vaidya, B. et al. The cytotoxic T lymphocyte antigen-4 is a major Graves\u2019 disease locus. Hum. Mol. Genet. 8, 1195\u20131199 (1999).","journal-title":"Hum. Mol. Genet."},{"key":"2810_CR405","first-page":"31","volume":"69","author":"L Sun","year":"2023","unstructured":"Sun, L., Niu, T. & Zhang, Y. Association between thyroid cancer and CTLA-4 gene polymorphisms. Cell. Mol. Biol. (Noisy-le.-Gd.) 69, 31\u201336 (2023).","journal-title":"Cell. Mol. Biol. (Noisy-le.-Gd.)"},{"key":"2810_CR406","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/08916930500050319","volume":"38","author":"Y Ban","year":"2005","unstructured":"Ban, Y. et al. Association of a CTLA-4 3\u2019 untranslated region (CT60) single nucleotide polymorphism with autoimmune thyroid disease in the Japanese population. Autoimmunity 38, 151\u2013153 (2005).","journal-title":"Autoimmunity"},{"key":"2810_CR407","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2024.110338","volume":"267","author":"H Ohtani","year":"2024","unstructured":"Ohtani, H. et al. Effect of DNA methylation at the CTLA4 gene on the clinical status of autoimmune thyroid diseases. Clin. Immunol. 267, 110338 (2024).","journal-title":"Clin. Immunol."},{"key":"2810_CR408","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s10875-012-9721-0","volume":"32","author":"N Inoue","year":"2012","unstructured":"Inoue, N. et al. Associations between autoimmune thyroid disease prognosis and functional polymorphisms of susceptibility genes, CTLA4, PTPN22, CD40, FCRL3, and ZFAT, previously revealed in genome-wide association studies. J. Clin. Immunol. 32, 1243\u20131252 (2012).","journal-title":"J. Clin. Immunol."},{"key":"2810_CR409","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.dld.2008.09.001","volume":"41","author":"C Tolone","year":"2009","unstructured":"Tolone, C. et al. A common CTLA4 polymorphism confers susceptibility to autoimmune thyroid disease in celiac children. Dig. Liver Dis. 41, 385\u2013389 (2009).","journal-title":"Dig. Liver Dis."},{"key":"2810_CR410","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1167\/iovs.07-1433","volume":"49","author":"KK Chong","year":"2008","unstructured":"Chong, K. K. et al. Association of CTLA-4 and IL-13 gene polymorphisms with Graves\u2019 disease and ophthalmopathy in Chinese children. Investig. Ophthalmol. Vis. Sci. 49, 2409\u20132415 (2008).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"2810_CR411","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/sj.gene.6363869","volume":"3","author":"XB Wang","year":"2002","unstructured":"Wang, X. B., Zhao, X., Giscombe, R. & Lefvert, A. K. A CTLA-4 gene polymorphism at position-318 in the promoter region affects the expression of protein. Genes Immun. 3, 233\u2013234 (2002).","journal-title":"Genes Immun."},{"key":"2810_CR412","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1631\/jzus.2006.B0887","volume":"7","author":"Q Zhang","year":"2006","unstructured":"Zhang, Q., Yang, Y. M. & Lv, X. Y. Association of Graves\u2019 disease and Graves\u2019 ophthalmopathy with the polymorphisms in promoter and exon 1 of cytotoxic T lymphocyte associated antigen-4 gene. J. Zhejiang Univ. Sci. B. 7, 887\u2013891 (2006).","journal-title":"J. Zhejiang Univ. Sci. B."},{"key":"2810_CR413","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","volume":"17","author":"JJ Wright","year":"2021","unstructured":"Wright, J. J., Powers, A. C. & Johnson, D. B. Endocrine toxicities of immune checkpoint inhibitors. Nat. Rev. Endocrinol. 17, 389\u2013399 (2021).","journal-title":"Nat. Rev. Endocrinol."},{"key":"2810_CR414","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1530\/ERC-13-0499","volume":"21","author":"M Ryder","year":"2014","unstructured":"Ryder, M. et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr. Relat. Cancer 21, 371\u2013381 (2014).","journal-title":"Endocr. Relat. Cancer"},{"key":"2810_CR415","doi-asserted-by":"publisher","first-page":"1020709","DOI":"10.3389\/fpubh.2022.1020709","volume":"10","author":"X Hu","year":"2022","unstructured":"Hu, X. et al. Global prevalence and epidemiological trends of Hashimoto\u2019s thyroiditis in adults: A systematic review and meta-analysis. Front Public Health 10, 1020709 (2022).","journal-title":"Front Public Health"},{"key":"2810_CR416","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-018-0073-4","volume":"5","author":"MH Tan","year":"2019","unstructured":"Tan, M. H. et al. Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports. Clin. Diab. Endocrinol. 5, 1 (2019).","journal-title":"Clin. Diab. Endocrinol."},{"key":"2810_CR417","doi-asserted-by":"crossref","unstructured":"Mullard, A. LAG3 pushes immuno-oncology\u2019s leading edge. Nat. Rev. Drug Discov. 21, 167\u2013169 (2022).","DOI":"10.1038\/d41573-022-00036-y"},{"key":"2810_CR418","doi-asserted-by":"publisher","first-page":"e000957","DOI":"10.1136\/jitc-2020-000957","volume":"8","author":"JM Chauvin","year":"2020","unstructured":"Chauvin, J. M. & Zarour, H. M. TIGIT in cancer immunotherapy. J. Immunother. Cancer 8, e000957 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"2810_CR419","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s43556-025-00267-6","volume":"6","author":"Z Yan","year":"2025","unstructured":"Yan, Z. et al. TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives. Mol. Biomed. 6, 27 (2025).","journal-title":"Mol. Biomed."},{"key":"2810_CR420","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","volume":"44","author":"AC Anderson","year":"2016","unstructured":"Anderson, A. C., Joller, N. & Kuchroo, V. K. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity 44, 989\u20131004 (2016).","journal-title":"Immunity"},{"key":"2810_CR421","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1097\/CM9.0000000000001981","volume":"135","author":"L Zhao","year":"2022","unstructured":"Zhao, L. et al. Update on lymphocyte-activation gene 3 (LAG-3) in cancers: from biological properties to clinical applications. Chin. Med. J. (Engl.) 135, 1203\u20131212 (2022).","journal-title":"Chin. Med. J. (Engl.)"},{"key":"2810_CR422","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50007-7","volume":"15","author":"S Saevarsdottir","year":"2024","unstructured":"Saevarsdottir, S. et al. Start codon variant in LAG3 is associated with decreased LAG-3 expression and increased risk of autoimmune thyroid disease. Nat. Commun. 15, 5748 (2024).","journal-title":"Nat. Commun."},{"key":"2810_CR423","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1210\/jc.2018-00498","volume":"103","author":"M Vitales-Noyola","year":"2018","unstructured":"Vitales-Noyola, M. et al. Patients with autoimmune thyroiditis show diminished levels and defective suppressive function of Tr1 regulatory lymphocytes. J. Clin. Endocrinol. Metab. 103, 3359\u20133367 (2018).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2810_CR424","first-page":"3557","volume":"104","author":"R Giannini","year":"2019","unstructured":"Giannini, R. et al. Immune profiling of thyroid carcinomas suggests the existence of two major phenotypes: an ATC-like and a PDTC-like. J. Clin. Endocrinol. Metab. 104, 3557\u20133575 (2019).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2810_CR425","doi-asserted-by":"publisher","first-page":"e005225","DOI":"10.1136\/jitc-2022-005225","volume":"10","author":"MJ Kroloff","year":"2022","unstructured":"Kroloff, M. J. et al. Durable response of anaplastic thyroid carcinoma to FS118, a bispecific LAG-3\/PD-L1 antibody, after checkpoint inhibitor progression: a case report. J. Immunother. Cancer 10, e005225 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"2810_CR426","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2174\/1566524018666180705105753","volume":"18","author":"J Zhao","year":"2018","unstructured":"Zhao, J. et al. Decreased expression of TIM-3 on Th17 Cells Associated With Ophthalmopathy In Patients with Graves\u2019 disease. Curr. Mol. Med. 18, 83\u201390 (2018).","journal-title":"Curr. Mol. Med."},{"key":"2810_CR427","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.bbrc.2017.07.144","volume":"491","author":"LH Luo","year":"2017","unstructured":"Luo, L. H. et al. Tim3\/galectin-9 alleviates the inflammation of TAO patients via suppressing Akt\/NF-kB signaling pathway. Biochem. Biophys. Res. Commun. 491, 966\u2013972 (2017).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2810_CR428","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1210\/clinem\/dgaa701","volume":"106","author":"X Shi","year":"2021","unstructured":"Shi, X. et al. Immune co-inhibitory receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in medullary thyroid cancers: a large cohort study. J. Clin. Endocrinol. Metab. 106, 120\u2013132 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2810_CR429","doi-asserted-by":"publisher","first-page":"17648","DOI":"10.1002\/cam4.6382","volume":"12","author":"Y Shao","year":"2023","unstructured":"Shao, Y. et al. Serum soluble immune checkpoint levels predict cervical lymph node metastasis of differentiated thyroid carcinoma patients. Cancer Med. 12, 17648\u201317659 (2023).","journal-title":"Cancer Med."},{"key":"2810_CR430","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1158\/2326-6066.CIR-14-0201","volume":"3","author":"JJ Severson","year":"2015","unstructured":"Severson, J. J. et al. PD-1+Tim-3+ CD8+ T lymphocytes display varied degrees of functional exhaustion in patients with regionally metastatic differentiated thyroid cancer. Cancer Immunol. Res. 3, 620\u2013630 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"2810_CR431","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-01113-4","volume":"22","author":"T Nakazawa","year":"2022","unstructured":"Nakazawa, T. et al. Expression of T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT) in anaplastic thyroid carcinoma. BMC Endocr. Disord. 22, 204 (2022).","journal-title":"BMC Endocr. Disord."},{"key":"2810_CR432","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1038\/s41417-023-00663-6","volume":"30","author":"C Feng","year":"2023","unstructured":"Feng, C. et al. Integrative single-cell transcriptome analysis reveals immune suppressive landscape in the anaplastic thyroid cancer. Cancer Gene Ther. 30, 1598\u20131609 (2023).","journal-title":"Cancer Gene Ther."},{"key":"2810_CR433","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1055\/a-0597-8948","volume":"127","author":"M \u0160tefani\u0107","year":"2019","unstructured":"\u0160tefani\u0107, M., Toki\u0107, S., Suver-Stevi\u0107, M. & Glava\u0161-Obrovac, L. Expression of TIGIT and FCRL3 is altered in T cells from patients with distinct patterns of chronic autoimmune thyroiditis. Exp. Clin. Endocrinol. Diabetes 127, 281\u2013288 (2019).","journal-title":"Exp. Clin. Endocrinol. Diabetes"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02810-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02810-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02810-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:02:50Z","timestamp":1788303770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02810-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":433,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2810"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02810-5","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"7 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests. Yongguang Tao is the editorial board member of Signal Transduction and Targeted Therapy, but he has not been involved in the process of manuscript handling.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"360"}}